

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07H 19/16, 19/167, A61K 31/70</b>		A1	(11) International Publication Number: <b>WO 95/07921</b> (43) International Publication Date: 23 March 1995 (23.03.95)
(21) International Application Number:	PCT/DK94/00344	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date:	15 September 1994 (15.09.94)		
(30) Priority Data:	1043/93 0310/94	17 September 1993 (17.09.93) 16 March 1994 (16.03.94)	DK
(71) Applicant (for all designated States except US):	NOVO NORDISK A/S [DK/DK]; Novo Alle, DK-2880 Bagsværd (DK).	Published	<i>With international search report</i>
(72) Inventors; and			
(75) Inventors/Applicants (for US only):	LAU, Jesper [DK/DK]; Rosenvænget 3, DK-2530 Farum (DK). KNUTSEN, Lars, Jacob, Stray [GB/DK]; Aldersrovej 7, DK-2950 Vedbæk (DK).		
(74) Agent:	HOUØLLER, Peter; Novo Nordisk A/S, Novo Alle, DK-2880 Bagsværd (DK).		

(54) Title: CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE

(57) Abstract

A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein X is halogen, amino, perhalomethyl, cyano, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino; A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl; R<sup>1</sup> is selected from optionally substituted N-bonded heterocyclics. The compounds have been found useful for treating central nervous system ailments.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Chemical Compounds their Preparation and Use

5

The present invention relates to therapeutically active *N*-substituted 5'-deoxy adenosine derivatives further substituted at the 2- and 5' positions and pharmaceutically acceptable addition salts thereof, and their pharmaceutical compositions as well as methods for using the compounds and 10 compositions described.

Background of the Invention

Adenosine is a naturally occurring purine nucleoside, from which is derived a range of agonists at adenosine receptors having considerable potential in the treatment of human disease (Life Sciences, 1991, 49, 15 1435-1453; Journal of Medicinal Chemistry, 1992, 35, 407-422; Annual Reports in Medicinal Chemistry, 1993, 28, 295-304).

Adenosine has been shown to have a number of significant effects on the mammalian central nervous system (CNS) (Annual Reports in Medicinal Chemistry, 1988, 23, 39-48; Adenosine in the Nervous System, T.W. Stone, Ed., Academic Press Ltd., London 1991) especially under conditions of neuronal stress where the compound appears to act as an 20 endogenous neuroprotectant (Progress in Neurobiology, 1988, 31, 85-108, Trends in Pharmacological Sciences, 1992, 11, 439-445). For example, the concentration of adenosine has been demonstrated to rise 25 greatly in certain brain regions following epileptic seizures or conditions of neuronal ischaemia/anoxia (Brain Research, 1990, 516, 248-256).

30

It has been established for some years now that centrally acting adenosine receptor agonists or compounds which increase extracellular adenosine levels can exhibit what is termed neuromodulator activity

- 2 -

(Trends in Neurosciences, 1984, 164-168). Such substances influence the release of neurotransmitters in regions of the central nervous system (Annual Review of Neuroscience, 1985, 8, 103-124; Trends in Neurosciences, 1984, 164-168), with particular inhibitory effects on the release 5 of the excitatory amino acid glutamic acid (glutamate) in the CNS (Nature, 1985, 316, 148-150) especially under ischaemic conditions (Journal of Neurochemistry, 1992, 58, 1683-1690).

There are several CNS ailments for which this adenosine receptor mediated neuromodulator activity is accepted by persons skilled in the art as being of clear therapeutic benefit including the treatment of convulsive disorders (European Journal of Pharmacology, 1991, 195, 261-265; Journal of Pharmacology and Experimental Therapeutics, 1982, 220, 70-76; European Journal of Pharmacology, 1993, 242, 221-228),  
10 prevention of neurodegeneration under conditions of brain anoxia/ischaemia (Neuroscience Letters, 1987, 83, 287-293; Stroke, 1988, 19, 1133-1139; Neuroscience, 1989, 30, 451-462; Pharmacology of Cerebral Ischaemia 1990, (Kriegelstein, J. and Oberpichler, H., Eds., Wissenschaftliche Verlagsgesellschaft mbH: Stuttgart, 1990, pp  
15 439-448; Trends in Pharmacological Sciences 1992, 11, 439-445) or the use of a purinergic agent in the treatment of pain (European Journal of Pharmacology, 1989, 162, 365-369; Neuroscience Letters, 1991, 121, 267-270).  
20  
25 Adenosine receptors represent a subclass ( $P_1$ ) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. This subclass has been further classified into distinct receptor types which have become known as  $A_1$ ,  $A_2$  and  $A_3$ . Extensive research has been carried out in a quest to identify selective ligands at these sites. Selective  
30 ligands exist for  $A_1$ ,  $A_2$  and  $A_3$  adenosine receptors and the structure-activity relationships of the various reference ligands have been reviewed

- 3 -

(Comprehensive Medicinal Chemistry, Volume 3, (Hansch, C., Sammes, P.G. and Taylor, J.B., Eds., Pergamon Press PLC: 1990, pp 601-642, Journal of Medicinal Chemistry, 1994, 37, 636 - 646). Among the known adenosine receptor agonists most selective for the A<sub>1</sub> receptor over the A<sub>2</sub> receptor are the examples where the adenine nucleus is substituted with a cycloalkyl group on the amino function, for example N-cyclopentyladenosine (CPA) and N-cyclohexyladenosine (CHA) (Journal of Medicinal Chemistry, 1985, 28, 1383-1384) or 2-chloro-N-cyclopentyladenosine (CCPA) (Naunyn-Schmiedeberg's Arch. Pharmacol. 1988, 337, 687-689).

There is evidence for further subdivision of adenosine receptors into the subtypes A<sub>2a</sub>, A<sub>2b</sub> (of high and low affinity) A<sub>3</sub> and A<sub>4</sub>. The latest status of these subtypes has been reviewed (Drug Development Research, 1993, 28, 207-213; Trends in Pharmacological Sciences 1993, 290-291; Pharmacological Reviews, 1994, 46, 143-156). The A<sub>3</sub> receptor (Proceedings of the National Academy of Sciences of the USA, 1992, 89, 7432-7436; Trends in Pharmacological Sciences, 1994, 15, 298-306) appears to be responsible for some of the cardiovascular effects of reference ligands (British Journal of Pharmacology, 1993, 109, 3-5).

Various examples of N-heteroarylalkyl substituted A<sub>1</sub> selective adenosine analogues have been reported in the literature. It should be noted that some of these are named as N<sup>6</sup>-substituted adenosine derivatives, but this is equivalent to ACS-approved nomenclature where compounds substituted on adenosine's 6-amino position are referred to as N-substituted adenosine derivatives. Derivatives of adenosine with the heteroatoms sulphur, oxygen or nitrogen bonded directly to the 6-amino substituent are not common in the chemical literature, but those cases known are summarised below.

- 4 -

Derivatives with hydrogen at the purine 2-position include *N*-aminoadenosine, *N*-[(*N*-methyl-*N*-phenyl)amino]adenosine, *N*-hydroxyadenosine, *N*-methoxyadenosine and *N*-benzyloxyadenosine (Journal of Medicinal Chemistry, 1985, 28, 1636-1643); *N*-ethoxyadenosine (Chemical and Pharmaceutical Bulletin, 1973, 21, 1676-1682; *ibid.*, 1973, 21, 1835-1838); *N*-(methylamino) adenosine and *N*-[*(N*-hydroxy-*N*-methyl)-amino]adenosine (Journal of Medicinal Chemistry, 1968, 11, 521-523). A range of compounds which have no further substitution on the ribose moiety have been published by Novo Nordisk (Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666).

Examples of adenosine derivatives with oxygen or nitrogen atoms bonded to the 6-amino substituent, containing an additional purine 2-substituent are 2-amino-*N*-hydroxyadenosine (Journal of Medicinal Chemistry, 1972, 15, 387-390); 2-amino-*N*-aminoadenosine (Chemical and Pharmaceutical Bulletin, 1969, 17, 2373-2376); 2-amino-*N*-methoxyadenosine (Chemical and Pharmaceutical Bulletin, 1975, 23, 464-466); 2-chloro-*N*-hydroxyadenosine (Journal of Medicinal Chemistry, 1991, 34, 2226-2230), 2-fluoro-*N*-hydroxyadenosine and 2-fluoro-*N*-aminoadenosine (Journal of Medicinal Chemistry, 1970, 13, 427-430) and 2-fluoro-*N*-methoxyadenosine (Journal of Medicinal Chemistry, 1971, 14, 816-819). These articles involve compounds with intact ribose moieties.

In the above scientific articles, no mention is made of any pharmacological effects of the compounds concerned on the central nervous system.

There are also very few examples of compounds designed as adenosine receptor agonists where the ribose moiety in adenosine is chemically modified, and many of those known have poor affinity for the adenosine receptor (Journal of Medicinal Chemistry, 1986, 29, 346-353). How-

- 5 -

ever, minor modifications at the 3'- and 5'-positions appear to be allowed and amongst these the 5'-chloro-5'-deoxy adenosines show particularly good receptor affinity (Journal of Medicinal Chemistry, 1989, 32, 8-11). Other scientific articles also describe 5'-modifications of 5 adenosine derivatives (Journal of Medicinal Chemistry, 1986, 29, 1683-1689).

- EP Publications No. 181,128 and 181,129 disclose 5'-deoxy adenosine derivatives containing 5'-hydrogen, 5'-halogen and 5'-methylthio, which 10 are claimed to have desirable antiinflammatory, analgesic as well as CNS and antihypertensive properties respectively. EP Publication No. 232,813 discloses N-substituted adenosines including a larger range of 5'-modified compounds which are also claimed to have desirable CNS and antihypertensive properties. PCT Publication WO 94/02497 reveals 15 certain sulphohydrocarbon derivatives of adenosine, where the possibility exists for substitution at the 5'-position of the ribose moiety.
- In PCT Publication WO 88/03147 5'-substituted adenosine derivatives with selectivity for the adenosine A2 receptor are disclosed.
- 20 In US Patent No. 4,962,194 methods for preparing 5', N-disubstituted adenosine derivatives are revealed. GB Patent No. 1,101,108 discloses 5', N-disubstituted adenosine analogues which possess cardiovascular activity. US Patent No. 3,910,885 reveals 4'-alkoxy and 4'-haloalkoxy nucleosides. PCT Publication WO 94/06348 discloses a number of 25 pyrrolo[3,4-d]pyrimidine structures which are formally isosteric with adenosine and which are modified with substituents at the sugar 5'-position. US Patent No. 5308837 covers the use of 5'-amine substituted adenosine analogues as immunosuppressants.
- 30 In US Patent No. 3,819,613, substituted adenosine analogues with hydrazone derivatives on the 6-amino function are disclosed as

- 6 -

hypotensive agents. In GB Patent No. 1,351,501, adenosine and 2-aminoadenosine derivatives having a -NH-R<sub>2</sub> group joined to the 6-amino function are disclosed as coronary dilators and platelet aggregation inhibitors. In EP Publication No. 152,944, a series of 2-, 6- and 8-  
5 substituted adenosine derivatives are described having activity as anti-allergy agents. In EP Publication No. 253,962, adenosine and 2-halo-adenosine analogues having an alkyl, cycloalkyl or an aralkyl group attached to the 6-amino function are described with activity as anti-dementia agents.  
10 In EP Publication No. 402,752, derivatives of adenosine unsubstituted in the 2-position are described which have a substituted heteroaromatic 1-pyrrolyl moiety attached to the 6-amino group. In PCT Publication No. WO 91/04032, methods of preventing neural tissue damage in neuro-degenerative diseases by increasing extracellular concentrations of adenosine are described. Examples are given of prodrug esters of AICA riboside which are claimed to be centrally acting neuroprotective agents.  
15 In PCT Publication No. WO 92/02214, analogues of AICA riboside are described which increase extracellular adenosine levels with beneficial effects claimed in peripheral and CNS ischaemia. In PCT Publication No. WO 90/05526, 2-(alkylalkynyl)adenosine derivatives are described for treatment of ischaemic disease of the heart and brain. In EP Publication No. 423 777 a method for treating gastrointestinal motility disorders using N(6) (substituted aminoalkyl) adenosine derivatives is disclosed. EP  
20 Publication No. 490 818 describes a new use of 2'-O-methyl adenosine derivatives for a range of ailments including neurodegenerative disorders.  
25

The present invention relates to new adenosine analogues with modified ribose moieties which show potent binding *in vitro* to the adenosine A<sub>1</sub> receptor, and which also display selectivity for A<sub>1</sub> receptor binding *in vitro* over that to the A<sub>2</sub> receptor subtype. In addition, the compounds  
30

- 7 -

contained in this invention have a relatively high lipophilicity, especially when compared to adenosine analogues which are not substituted on the 6-amino group or the purine 2-position. This latter property makes these compounds suitable for passage across the blood brain barrier.


5

The compounds are also substrates for nucleoside-specific active transport systems into the CNS across the blood barrier. These useful properties support the notion that the compounds are candidate drugs for treatment of the CNS ailments mentioned within this invention in

10 humans as well as cardiovascular disorders such as cardiac ischaemia.

The compounds of the invention are purine derivatives of formula I, or a pharmaceutically acceptable salt thereof:

15



(I)

20

wherein


25 X is halogen, amino, perhalomethyl, cyano, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino;

A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;

30

R<sup>1</sup> is selected from the groups consisting of


- 8 -



(a)

- wherein Q is nitrogen or carbon, n is 1 to 3 and where the group (a) may be optionally substituted with one or two C<sub>1-6</sub>-alkyl groups, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, phenoxy, phenylsulphonyl, phenylsulphanyl, phenylthio, hydroxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, phenylthioalkyl or
- 5      C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, phenylthioalkyl or

10



(b)

- 15      wherein Y is O, S or NZ, where Z is H, C<sub>1-6</sub>-alkyl or phenyl, and where the group (b) may be optionally substituted with C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, phenoxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, or

R<sup>1</sup> is -NR<sup>2</sup>R<sup>3</sup> or -YR<sup>4</sup>,

20      wherein Y is oxygen;

R<sup>2</sup> is C<sub>1-6</sub>-alkyl;

R<sup>3</sup> is phenyl or C<sub>1-6</sub>-alkyl which may be substituted by phenyl or phenoxy;

R<sup>4</sup> is C<sub>1-6</sub>-alkyl or C<sub>3-8</sub>-cycloalkyl, which may be substituted by phenyl or


25      phenoxy.

In certain examples, the group R<sup>1</sup> can contain one or more asymmetric carbon atoms in addition to those asymmetric centres already present in the molecule. In examples where this is the case, this invention includes  
30      all resulting diastereoisomers and mixtures thereof.

- 9 -

- Various salts of compounds of formula (I) can be prepared which is physiologically acceptable. These include addition salts derived from inorganic or organic acids, for example, acetates, fumarates, glutarates, glutaconates, lactates, maleates, methanesulphonates, phosphates, 5 salicylates, succinates, sulphates, sulphamates, tartrates and para-toluenesulphonates. In some cases, solvates of either the free nucleosides or the acid addition salts can be isolated and these solvates may, for example, be hydrates or alcoholates.
- 10 Compounds of formula (I), which act as adenosine receptor agonists, are useful in the treatment of central nervous system conditions such as anxiety, neuronal ischaemia/anoxia, convulsive disorders (epilepsy) and neurodegeneration (including Parkinson's disease) in humans. This includes treating disorders where the blood flow to the brain is interrupted, for example during traumatic head injury, cardiac arrest and stroke. Further, the compounds of formula (I) are useful as analgesic agents, in lowering plasma free fatty acid (FFA) levels or as cardiovascular agents, e.g. treatment of myocardial ischaemia.
- 15
- 20 The compounds according to the invention are prepared as follows:

General Method A



- 10 -

A compound of general formula (V) may be prepared by reacting a substance of general formula (VIII) (prepared according to general method B), where B represents a hydrogen, a halogen, a pseudohalogen, an  
 5 alkoxy, or a thioalkoxy group and R<sup>6</sup> and R<sup>7</sup> represent hydrogen or a hydroxyl protecting group such as benzoyl, p-tolyl, lower alkanoyl, an alkylated silyl group, or alternatively the two R<sup>6</sup> may together represent a 1-methylethylidene with R<sup>7</sup> being defined as above, with a purine derivative (II) where X and L each represents a halogen, an alkoxy or a thio-  
 10 alkoxy group or a (protected) amino group, giving the reaction product (III) alone or together with the corresponding  $\alpha$ -anomer. Substitution of L in compound (III) with an alkylated amine, an alkylated hydroxylamine or a functionalised hydrazine of general formula (VI) will give compound (IV). The corresponding  $\alpha$ -anomer of compound (III) may be reacted in a  
 15 similar way. Depending upon the nature of group R<sup>6</sup> deprotection of a compound of formula IV can be performed according to the art known (Greene, T.W., Protective Groups in Organic Synthesis, 2nd ed., 1991), to give a compound of formula V, which is a compound of formula I,  
 20



25

30


wherein A is methyl, chloromethyl, fluoromethyl, cyanomethyl, amino-

- 11 -

methyl, methylthiomethyl or methoxymethyl.

#### **General Method B:**

5




10

A compound of formula (VIII) where B, R<sup>6</sup> and R<sup>7</sup> are defined as in general method A, can be prepared from a compound (VII), where R<sup>6</sup> and R<sup>7</sup> are defined as in formula (I) and R<sup>5</sup> represents a hydroxy group or a suitable leaving group such as a halogen or a halogenated sulphonate. In cases where R<sup>5</sup> represents a hydroxy group, this can be directly alkylated to an alkoxy group with an alkylating reagent, or it can be halogenated with a suitable halogenation reagent to give compound (VIII). Alternatively, the group B may be introduced by reacting a compound (VII) where R<sup>5</sup> represents a leaving group, with a nucleophilic reagent containing nucleophiles such as an alkoxide, thioalkoxide, or halide (incl. pseudo-halides). In cases where B represents a hydrogen, this may be introduced by reduction of compound (VII) where R<sup>5</sup> represents a hydroxyl or a suitable leaving group with a reducing reagent. The protecting groups R<sup>6</sup> and R<sup>7</sup> can be removed as described (Greene, T.W., Protective Groups in Organic Synthesis, 2nd ed. 1991).

- 12 -

General Method C:



A compound of formula (V) where B, X and R<sup>1</sup> are defined as in general method A, can be prepared from a compound (IX) where R<sup>6</sup> is defined as in formula (VIII) and R<sup>5</sup> represents a hydroxy group or a suitable leaving group such as a halogen or an halogenated sulphonate. In cases where R<sup>5</sup> represents a hydroxy group this can be directly alkylated to an alkoxy group with an alkylating reagent, or it can be halogenated with a suitable halogenation reagent to give compound (X). Alternatively, the group B may be introduced by reacting a compound (IX) where R<sup>5</sup> represents a leaving group with a nucleophilic reagent containing nucleophiles such as an alkoxide, thioalkoxide, or halide (incl. pseudohalides).

In cases where B represents a hydrogen this may be introduced by reduction of compound (IX) where R<sup>5</sup> represents a hydroxyl or a suitable leaving group, with a reducing reagent. The protecting groups R<sup>6</sup> of formula (X) can be removed as described in the art known (Greene, T.W., Protective Groups in Organic Synthesis, 2nd ed 1991), to give a compound of formula V, which is a compound of formula I,

- 13 -

5



wherein A is methyl, chloromethyl, fluoromethyl, cyanomethyl, amino-methyl, methylthiomethyl or methoxymethyl.

- 10 Methods for assessing adenosine receptor binding *in vitro* have been reviewed [Adenosine Receptors, Cooper, D.M.F. and Londos, C., Eds., Alan R. Liss, Inc.: New York, 1988, 43-62].

15 Evaluation of these compounds in established animal models has indicated that the compounds according to the invention possess desirable central nervous system properties. For example, they act as anticonvulsant agents, are effective in animal models of pain, and show cerebroprotective effects in laboratory test animals subjected to simulated cerebral ischaemia. In addition, the compounds may have efficacy  
20 as neuroprotective agents in cases of cerebral oedema and traumatic head injury.

Evaluation of *in vitro* binding to adenosine A<sub>1</sub> and A<sub>2</sub> receptors.

- 25 The affinity of the novel compounds described in this invention for the adenosine A<sub>1</sub> receptor was determined essentially as described in the literature using [<sup>3</sup>H]-R-PIA as a radioligand (Naunyn-Schmiedeberg's Archives of pharmacology, 1980, 313, 179-187). Affinity for the A<sub>2</sub> receptor was measured using the radioligand [<sup>3</sup>H]-CGS 21680 (European  
30 Journal of Pharmacology, 1989, 168, 243-246), and the values for representative compounds is given in the table below. *In vitro* receptor

- 14 -

binding values obtained for the reference standards CPA [*N*-(cyclopentyl)adenosine] and *R*-PIA [(*R*)-*N*-(1-phenyl-2-propyl)adenosine]) are included for comparison. The methods both for the above *in vitro* examination of the compounds and the method used for DMCM-induced seizures *in vivo* are summarized in the European Journal of Pharmacology, 1993, 224, 221-228.

The results obtained by testing selected compounds disclosed in the present invention are shown in the table I.

10

TABLE I

Adenosine agonist tested	A <sub>1</sub> Receptor Binding (Ki, nM)	A <sub>2</sub> Receptor Binding (Ki, nM)	Ratio A <sub>2</sub> /A <sub>1</sub>	DMCM-ind. seizures (ED <sub>50</sub> , mg/kg)
Example 1	6.4	2739	428	0.4
Example 11	11	6600	600	4.7
Example 12	74	4655	63	6.1
Example 18	5.3	2420	457	1.0
CPA	1.2	192	77	0.2
<i>R</i> -PIA	1.9	116	61	0.5

The compounds of the invention, together with a conventional adjuvant, carrier or diluent, and if desired in the form of a pharmaceutically acceptable acid addition salt thereof, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as

25

- 15 -

solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral use (including subcutaneous administration and infusion). Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the adenosine receptor agonist commensurate with the intended daily dosage range to be employed. Tablets containing ten (10) milligrams of active ingredient or, more broadly, ten (10) to hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.

The compounds of this invention can thus be used for the formulation of pharmaceutical preparation, e.g. for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy.

Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or enteral application which do not deleteriously react with the active compounds.

Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethyl-cellulose and polyvinylpyrrolidone.

The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteri-

- 16 -

ously react with the active compounds.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

Ampoules are convenient unit dosage forms.

Tablets, dragees, or capsules having talc and/or carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch, are particularly suitable for oral application. A syrup, elixir or the like can be used in cases where a sweetened vehicle can be employed.

Generally, the compounds of this invention are dispensed in unit form comprising 0.05-100 mg in a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is 0.1-300 mg/day, preferably 10-100 mg/day, when administered to patients, e.g. humans, as a drug.

A typical tablet which may be prepared by conventional tabletting techniques contains:

25	Active compound	5.0 mg
	Lactosum	67.0 mg Ph.Eur.
	Avicel™	31.4 mg
	Amberlite™IRP 88	1.0 mg
30	Magnesii stearas	0.25 mg Ph.Eur.

- 17 -

Owing to activity against pain or convulsive disorders and prevention of neurodegeneration under conditions of anoxia/ischaemia the compounds of the invention are extremely useful in the treatment of related symptoms in mammals, when administered in an amount effective for agonist 5 activity of compounds of the invention. The compounds of the invention may accordingly be administered to a subject, e.g., a living animal body, including a human, in need of adenosine receptor agonist, and if desired in the form of a pharmaceutically acceptable acid addition salt thereof (such as the hydrobromide, hydrochloride, or sulphate, in any event 10 prepared in the usual or conventional manner, e.g., evaporation to dryness of the free base in solution together with the acid), ordinarily concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or 15 parenteral (including subcutaneous) route, in an effective amount of adenosine receptor agonist, and in any event an amount which is effective for the treatment of anoxia, traumatic injury, ischemia, migraine or other pain symptoms, epilepsy, or neurodegenerative diseases owing to their adenosine receptor agonist activity. Suitable dosage ranges are 1- 20 200 milligrams daily, 10-100 milligrams daily, and especially 30-70 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician 25 or veterinarian in charge.

The preparation of compounds of formula (I) is further illustrated in the following examples.

30 Hereinafter, TLC is thin layer chromatography, THF is tetrahydrofuran, TFA is trifluoracetic acid and mp is melting point. Where melting points

- 18 -

are given, these are uncorrected. The structures of the compounds are confirmed by assignment of NMR spectra (from which representative peaks are quoted) and by microanalysis where appropriate. Compounds used as starting materials are either known compounds or compounds  
5 which can be prepared by methods known *per se*. Column chromatography was carried out on Merck silica gel 60 interfaced via a system module to a Waters 490 multiwavelength detector to a reversed phase C18 column (250 x 4 mm, 5 $\mu$ m, 100 $\text{\AA}$ ; eluent flow rate 1 mL/ min at 35°C). Retention times are given in minutes.

10

EXAMPLE 1

2,5'-Dichloro-5'-deoxy-N-(1-piperidinyl)adenosine

15 The title compound was prepared according to general method C.

2,5'-Dichloro-5'-deoxy-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)-adenosine

20 2-Chloro-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)adenosine [prepared by protection of 2-Chloro-N-(1-piperidinyl)adenosine (Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666)] (0.28 g, 0.47 mmol), tri-phenylphosphine (0.31 g, 1.18 mmol) and tetrachloromethane (0.18 g, 25 1.18 mmol) was stirred in dry dimethylformamide (10 ml) at 20°C for 48 h. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography eluting with dichloromethane and 10% ammonia in ethanol (95:5) to give 2,5'-dichloro-5'-deoxy--2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)adenosine (0.10 g, 48%) as  
30 a foam.  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.34 (3H, s, -CH<sub>3</sub>), 1.36 (2H, m, piperidine C-H), 1.62 (4H, m, piperidine C-H), 2.82 (4H, br, piperidine C-

- 19 -

H), 3.78, 3.88 (2H, ABX, H-5' and H-5'), 4.35 (1H, ddd, H-4'), 5.02 (1H, dd, H-3'), 5.39 (1H, dd, H-2'), 6.20 (1H, d, H-1'), 8.36 (1H, s, H-8). HPLC retention time 21.45 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water).

5

Deprotection of 2,5'-dichloro-5'-deoxy-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)adenosine (0.11 g, 0.25 mmol) was performed by dissolving the compound in a mixture of ethanol (5 ml) and sulphuric acid (0.2M, 5 ml) and stirring the mixture for 72 h. at room temperature. The 10 reaction mixture was neutralized with aqueous sodium bicarbonate and extracted with dichloromethane (3 x 50 ml). The organic phase was dried ( $MgSO_4$ ) and evaporated in vacuo. The product was purified by flash chromatography on silica gel, eluting with a mixture of dichloromethane and 10% ammonia solution in ethanol (9:1), to provide the title 15 2,5'-dichloro-5'-deoxy-N-(1-piperidinyl)adenosine (0.1 g, 99%) as a foam,  $^1H$ -NMR (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.35 (2H, br, piperidine C-H), 1.62 (4H, br, piperidine C-H), 2.80 (4H, br, piperidine C-H), 3.82, 3.93 (1H, ABX, H-5' and H-5'), 4.10 (1H, dd, H-4'), 4.18 (1H, dd, H-3'), 4.63 (1H, dd, H-2'), 5.88 (1H, d, H-1'), 8.39 (1H, s, H-8). HPLC retention 20 time 10.95 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 99% purity at 250 nm).

#### EXAMPLE 2

25 (S)-2,5'-Dichloro-5'-deoxy-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine

The title compound was prepared according to general method C. (S)-2-Chloro-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine [Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal 30 Chemistry Letters, 1993, 3, 2661-2666] (0.35 g, 0.8 mmol) was dissolved in acetonitrile (5 ml) and cooled on an ice-water bath. Under a

- 20 -

nitrogen atmosphere, thionyl chloride (0.34 g, 0.2 ml, 2.4 mmol) (see Borchardt, R.T., Huber, J.A. and Wu, Y.S., Journal of Organic Chemistry, 1976, 41, 565-567) was added and a precipitate appeared which dissolved over the following 15 min. Pyridine (0.13 ml, 0.13 g, 1.6 mmol) was introduced gradually, the reaction mixture became yellow in colour and was allowed to reach room temperature gradually. After stirring the mixture overnight, ice was added and the reaction mixture was neutralised to pH 7 with aqueous sodium bicarbonate prior to extraction with ethyl acetate (2 x 10 ml). The combined extracts were dried ( $\text{MgSO}_4$ ) and evaporated to provide the intermediate 2,3-O-sulphinyl derivative (0.35 g), to which was added methanol (5 ml), water (1 ml) and 25% aqueous ammonia solution (0.25 ml) and this mixture was stirred for 16 h. The solution was evaporated in vacuo, and the resultant residue was purified by flash chromatography on silica gel eluting with a mixture of dichloromethane and 10% ammonia in ethanol (17:3), to provide the title (S)-2,5'-dichloro-5'-deoxy-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine (0.12 g, 34%) as a foam,  $^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.50 - 1.60 (1H, br, pyrrolidine C-H), 1.78 (2H, br q, pyrrolidine C-H), 1.92 - 2.03 (1H, br, pyrrolidine C-H), 3.85, 3.95 (2H, ABX, H-5' and H-5' $'$ ), 4.09 (1H, br dd, H-4'), 4.17 (1H, dd, H-3'), 4.67 (1H, dd, H-2'), 5.49, 5.62 (2H, 2d, 2'- and 3'-OH), 5.87 (1H, d, H-1'), 8.38 (1H, s, H-8), 9.34 (1H, br s, -NH). HPLC retention time 9.65 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 99% purity at 250 nm).

$\text{C}_{16}\text{H}_{22}\text{Cl}_2\text{N}_6\text{O}_4$ . 0.25  $\text{H}_2\text{O}$  requires C, 43.9; H, 5.2; N, 19.2. Found: C, 43.7; H, 5.4; N, 19.4%.

EXAMPLE 3

30

2,5'-Dichloro-5'-deoxy-N-(4-phenoxy-1-piperidinyl)adenosine

- 21 -

This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-*N*-(4-phenoxy-1-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (0.5 g, 1.05 mmol) was subjected to the chlorination conditions described above, providing the title compound

5      2,5'-dichloro-5'-deoxy-*N*-(4-phenoxy-1-piperidinyl)adenosine which precipitated on treatment with dichloromethane following trituration with ether. Drying in vacuo provided a solid (0.28 g, 56%), m.p. 165-170°C, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.74 - 1.84 (2H, br, piperidine C-H), 1.99 - 2.08 (2H, br, piperidine C-H), 2.80 - 2.90 (2H, br, piperidine C-H),

10     3.04 - 3.12 (2H, br, piperidine C-H), 3.85, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.09 (1H, q, H-4'), 4.18 (1H, q, H-3'), 4.44 (1H, br, PhO-C-H) 4.66 (1H, dd, H-2'), 5.50, 5.63 (2H, 2d, 2'- and 3'-OH), 5.89 (1H, d, H-1'), 6.94 (1H, t, Ar-H), 6.99 (2H, d, Ar-H), 7.30 (2H, t, Ar-H), 8.40 (1H, s, H-8). HPLC retention time 19.15 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 99.9% purity at 250 nm).

15

#### EXAMPLE 4

##### 2,5'-Dichloro-5'-deoxy-*N*-(3-methoxy-1-piperidinyl)adenosine

20     This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-*N*-(3-methoxy-1-piperidinyl)adenosine (prepared by *O*-methylation of *N*-tertbutyloxycarbonyl-3-hydroxypiperidine, followed by use of the *N*-amination technique described in Overberger, C.G. and Herin, L.P. Journal of Organic Chemistry, 1962, 27, 417, and further reaction of the resultant hydrazine as described in Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666) (0.1 g, 0.24 mmol) was subjected to the chlorination conditions described in Example 2, providing the title 2,5'-dichloro-5'-deoxy-*N*-(3-methoxy-1-piperidinyl)adenosine (mixture of diastereoisomers) (0.07 g, 67%), following column chroma-

25

30

- 22 -

tography, as a solid, m.p. 200 - 202°C.  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  3.86, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.11 (1H, q, H-4'), 4.19 (1H, q, H-3'), 4.65 (1H, dd, H-2'), 5.49, 5.62 (2H, 2d, 2'- and 3'-OH), 5.88 (1H, d, H-1'), 8.39 (1H, s, H-8). HPLC retention time 17.08 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 5 98.7% purity at 250 nm).

#### EXAMPLE 5

10      2,5'-Dichloro-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine

This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-N-(4-phenylthio-1-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (5.49 g, 11.1 mmol) was subjected 15 to the reaction conditions described above, providing the title 2,5'-dichloro-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine which precipitated from the aqueous methanolic ammonia. Recrystallization provided a solid (3.93 g, 69%), m.p. 154 - 157°C,  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.74 - 1.84 (2H, br, piperidine C-H), 1.95 - 2.05 (2H, br, piperidine C-H), 20 2.80 - 2.90 (1H, br, piperidine C-H), 3.04 - 3.12 (2H, br, piperidine C-H), 3.84, 3.93 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.17 (1H, q, H-3'), 4.64 (1H, dd, H-2'), 5.48, 5.62 (2H, 2d, 2'- and 3'-OH), 5.87 (1H, d, H-1'), 7.26 (1H, t, Ar-H), 7.35 (2H, t, Ar-H), 7.42 (2H, d, Ar-H), 8.38 (1H, s, H-8), 9.49 (1H, s, N-H). HPLC retention time 22.19 min. 25 (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 100% purity at 250 nm).

#### EXAMPLE 6

30

2,5'-Dichloro-5'-deoxy-N-(3-phenylthio-1-piperidinyl)adenosine

- 23 -

This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-N-(4-phenylthio-1-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (0.5 g, 1 mmol) was subjected to the reaction conditions described above, providing the title

- 5      2,5'-dichloro-5'-deoxy-N-(3-phenylthio-1-piperidinyl)adenosine (mixture of diastereoisomers) as a foam (0.48 g, 94%) following flash chromatography on silica gel.  $^1\text{H}$ -NMR (400MHz, DMSO-d<sub>6</sub>)  $\delta$  3.84, 3.92 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.17 (1H, q, H-3'), 4.64 (1H, dd, H-2'), 5.49, 5.62 (2H, 2d, 2'- and 3'-OH), 5.87 (1H, d, H-1'), 7.22 (1H, t, Ar-H), 7.31 (2H, t, Ar-H), 7.43 (2H, d, Ar-H), 8.39 (1H, s, H-8). HPLC retention time 17.08 min. (gradient elution over 30 min.; 20-80% acetonitrile/O.1% TFA in water, 98.7% purity at 250 nm).
- 10

EXAMPLE 7

15

2,5'-Dichloro-5'-deoxy-N-(4-phenylsulphinyl-1-piperidinyl)adenosine

- 20      2',3'-Di-O-acetyl-2,5'-dichloro-5'-deoxy-N-(4-phenylthio-1-piperidinyl)-adenosine (prepared by acetylation of Example 5) (2.95 g, 5 mmol) was dissolved in dry dichloromethane (100 ml). "Oxone" (7.7 g, 2.5 equiv.) and wet clay (Hirano, M., Tomaru, J. and Morimoto, T. Bull. Chem. Soc. Japan, 1991, 64, 3752-3754) (5.95 g) were introduced with vigorous stirring. Both the phenylsulphinyl product ( $R_f$  = 0.21) and the phenylsulphonyl product ( $R_f$  = 0.45) were apparent by TLC [SiO<sub>2</sub>, ethyl acetate/methanol (9:1)] and after 0.5 h. reaction time the reaction mixture was filtered. The filtrate was washed with water (2 x 100 ml), dried (MgSO<sub>4</sub>) and evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of ethyl acetate and heptane (1:1), then with ethyl acetate, and finally with a mixture of ethyl acetate and methanol (19:1), to provide 2',3'-di-O-acetyl-2,5'-dichloro-5'-deoxy-N-(4-phenylsulphinyl-1-piperidinyl)adenosine (0.18 g, 6%) and 2',3'-di-O-
- 25
- 30

- 24 -

acetyl-2,5'-dichloro-5'-deoxy-*N*-(4phenylsulphonyl-1-piperidinyl)-adenosine (1.2 g, 39 %) as foams.

**5'-Deoxy-2,5'-dichloro-*N*-(4-phenylsulphiny1-1-piperidinyl)adenosine**

5

2',3-Di-*O*-acetyl-2,5'-dichloro-5'-deoxy-*N*-(4-phenylsulphiny1-1-piperidinyl)adenosine (0.22 g, 0.36 mmol) was dissolved in methanol (10 ml) and methanolic ammonia (1 ml) was introduced. After 1 h. at room temperature, the reaction mixture was evaporated to a residue and

10 purified by flash chromatography on silica gel, eluting with a mixture of dichloromethane and ethanol (9:1) to provide 2,5'-dichloro-5'-deoxy-*N*-(4-phenylsulphiny1-1-piperidinyl)adenosine (0.1 g, 53%) as a foam.

<sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 3.84, 3.93 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.17 (1H, q, H-3'), 4.63 (1H, dd, H-2'), 5.49, 5.62

15 (2H, 2d, 2'- and 3'-OH), 5.87 (1H, d, H-1'), 7.53 - 7.66 (5H, m, Ar-H), 8.38 (1H, s, H-8). HPLC retention time 14.24 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 95.4% purity at 250 nm).

20

**EXAMPLE 8**

**2,5'-Dichloro-5'-deoxy-*N*-(4-phenylsulphonyl-1-piperidinyl)adenosine**

2',3-Di-*O*-acetyl-2,5'-dichloro-5'-deoxy*N*-(4-phenylsulphonyl-1-piperi-

25 dinyl)adenosine (generated during the preparation of Example 7) (1.2 g, 1.9 mmol) was dissolved in methanol (90ml) and methanolic ammonia (10 ml) was introduced. After 0.5 h. at room temperature, the reaction mixture was evaporated to a residue and purified by flash chromatography on silica gel, eluting with a mixture of dichloromethane and ethanol (9:1) to provide 2,5'-dichloro-5'-deoxy-*N*-(4-phenylsulphonyl-1-piperidi-  
30 ny1)adenosine (0.82 g, 79%) as a foam. <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ

- 25 -

3.84, 3.93 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.09 (1H, dt, H-4'), 4.16 (1H, ps t, H-3'), 4.62 (1H, dd, H-2'), 5.49, 5.62 (2H, 2d, 2'- and 3'-OH), 5.87 (1H, d, H-1'), 7.71 (2H, t, Ar-H), 7.80 (1H, t, Ar-H), 7.90 (1H, d, Ar-H), 8.39 (1H, s, H-8). HPLC retention time 13.78 min. (gradient elution over 5 30 min.; 20-80% acetonitrile/0.1% TFA in water, 96.9% purity at 250 nm).

#### EXAMPLE 9

10      2,5'-Dichloro-5'-deoxy-N-(4-phenyl-1-piperidinyl)adenosine

This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-N-(4-phenyl-1-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (0.3 g, 0.65 mmol) was subjected to the 15 chlorination conditions described above, providing the title 2,5'- dichloro-5'-deoxy-N-(4-phenyl-1-piperidinyl)adenosine as a foam (0.28 g, 90%), <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 3.86, 3.95 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.11 (1H, q, H-4'), 4.21 (1H, q, H-3'), 4.66 (1H, dd, H-2'), 5.49, 5.63 (2H, 2d, 2'- and 3'-OH), 5.89 (1H, d, H-1'), 7.20 (1H, dt, Ph-C-H), 20 7.31 (5H, d, Ar-H), 8.40 (1H, s, H-8), 9.45 (1H, s, N-H). HPLC retention time 20.92 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 99.75% purity at 250 nm).

#### EXAMPLE 10

25

2,5'-Dichloro-5'-deoxy-N-(1-morpholinyl)adenosine

This compound was prepared by the method described in Example 2. 2-Chloro-N-(1-morpholinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] 30 (1.0 g, 2.6 mmol) was subjected to the chlorination conditions described above, providing the title 2,5'-dichloro-5'-deoxy-N-(1-morpholinyl)-

- 26 -

adenosine as a foam (0.78 g, 74%),  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  2.38 (4H, br, morpholine C-H), 3.71 (4H, br, morpholine C-H), 3.85, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.18 (1H, q, H-3'), 4.64 (1H, q, H-2'), 5.50, 5.63 (1H, 2d, 2'-and 3'-OH), 5.88 (1H, d, H-1'), 8.41 (1H, s, H-8), 9.50 (1H, s, NH). HPLC retention time 7.82 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 97.8% purity at 250 nm).

5           C<sub>14</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>4</sub>.0.5 EtOH requires C, 42.1; H, 4.9; N, 19.6. Found: C, 10       41.6; H, 5.2; N, 19.0%.

#### EXAMPLE 11

##### 2,5'-Dichloro-5'-deoxy-N-(dimethylamino)adenosine

15           This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-N-(dimethylamino)adenosine [WO 93/23417 (Novo Nordisk A/S)] (0.62 g, 1.8 mmol) was subjected to the chlorination conditions described above, providing the title 20       2,5'-dichloro-5'-deoxy-N-(dimethylamino)adenosine as a solid (0.23 g, 41%) after column chromatography, m.p. 188-189°C,  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  2.59 (6H, s, N(CH<sub>3</sub>)<sub>2</sub>), 3.85, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.18 (1H, q, H-3'), 4.66 (1H, q, H-2'), 5.50, 5.62 (1H, 2d, 2'-and 3'-OH), 5.88 (1H, d, H-1'), 8.38 (1H, s, H-8), 9.39 (1H, br, NH).

25           C<sub>12</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>3</sub>.0.25 H<sub>2</sub>O. 0.25 EtOH requires C, 39.6; H, 4.8; N, 22.2. Found: C, 39.5; H, 4.5; N, 22.3%.

- 27 -

EXAMPLE 12

2,5'-Dichloro-5'-deoxy-N-methoxyadenosine

- 5 This compound was prepared by the method described in Example 2. 2-Chloro-*N*-(methoxy)adenosine [WO 93/23417 (Novo Nordisk A/S)] (0.8 g, 2.4 mmol) was subjected to the chlorination conditions described above, providing the title 2,5'-dichloro-5'-deoxy-*N*-methoxyadenosine as a foam (0.34 g, 40%),  $^1\text{H}$ -NMR (400MHz, DMSO- $d_6$ )  $\delta$  3.78 (3H, s, -OCH<sub>3</sub>), 3.85, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, q, H-4'), 4.19 (1H, q, H-3'), 4.66 (1H, q, H-2'), 5.51, 5.65 (1H, 2d, 2'-and 3'-OH), 5.90 (1H, d, H-1'), 8.45 (1H, s, H-8), 11.59 (1H, s, NH). HPLC retention time 6.99 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 96.5% purity at 250 nm).
- 10

15

EXAMPLE 13

*N*-Cyclopentoxy-2,5'-dichloro-5'-deoxy-adenosine

- 20 This compound was prepared by general method C, described in more detail in Example 2. *N*-Cyclopentoxy-2-chloroadenosine [WO 93/23417 (Novo Nordisk A/S)] (1.0 g, 2.6 mmol) was subjected to the chlorination conditions described above, providing the title *N*-cyclopentoxy-2,5'-dichloro-5'-deoxy-adenosine as a foam (0.82 g, 78%),  $^1\text{H}$ -NMR (400MHz, DMSO- $d_6$ )  $\delta$  1.49 - 1.92 (8H, 3m, cyclopentyl C-H), 3.86, 3.94 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.11 (1H, q, H-4'), 4.20 (1H, q, H-3'), 4.59 (1H, m, -OC-H), 4.67 (1H, q, H-2'), 5.51, 5.64 (1H, 2d, 2'-and 3'-OH), 5.90 (1H, d, H-1'), 8.44 (1H, s, H-8), 11.44 (1H, s, NH). HPLC retention time 12.2 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 97.4% purity at 250 nm).
- 25
- 30

- 28 -

$C_{15}H_{19}Cl_2N_5O_4$ .0.5 EtOH requires C, 45.0; H, 5.2; N, 16.4. Found: C, 45.2; H, 5.1; N, 16.2%.

EXAMPLE 14

5

2-Bromo-5'-chloro-5'-deoxy-N-(1-piperidinyl)adenosine

This compound was prepared by general method C, described in more detail in Example 2. 2-Bromo-N-(1-piperidinyl)adenosine [WO 93/23417 (Novo Nordisk A/S)] (0.06 g, 0.14 mmol) was subjected to the chlorination conditions described above, providing the title 2-bromo-5'-chloro-5'-deoxy-N-(1-piperidinyl)adenosine as a foam (0.016 g, 26%),  $^1H$ -NMR (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.37 (2H, br, piperidine C-H), 1.64 (4H, br, piperidine C-H), 2.80 (4H, br, piperidine C-H), 3.85, 3.93 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.09 (1H, q, H-4'), 4.18 (1H, q, H-3'), 4.65 (1H, q, H-2'), 5.48, 5.62 (1H, 2d, 2'-and 3'-OH), 5.87 (1H, d, H-1'), 8.33 (1H, s, H-8), 9.36 (1H, s, NH). HPLC retention time 9.65 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 94% purity at 250 nm).

20

EXAMPLE 15

2-Amino-5'-chloro-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine

25 This compound was prepared by general method C, described in more detail in Example 2. 2-Amino-N-(4-phenylthio-1-piperidinyl)adenosine [prepared by reaction of 9-(2,3,5-tri-O-acetyl- $\beta$ -D-ribofuranosyl)-9H-2-amino-6-chloro-9H-purine (Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666) with 1-amino-4-phenylthiopiperidine] (0.47 g, 1.0 mmol) was subjected to the chlorination conditions described above. Column

- 29 -

chromatography on silica gel, eluting initially with a mixture of heptane and ethyl acetate (7:3), increasing polarity to pure ethyl acetate provided the title 2-amino-5'-chloro-5'-deoxy-*N*-(4-phenylthio-1-piperidinyl)-adenosine (0.1 g, 20%) as a foam.  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.65  
5 (2H, dq, piperidine C-H), 1.91 - 2.01 (2H, br, piperidine C-H), 2.75 (2H, br t, piperidine C-H), 2.98 - 3.07 (2H, br, piperidine C-H), 3.82, 3.92  
(2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.04 (1H, dt, H-4'), 4.15 (1H, q, H-3'), 4.64  
(1H, dd, H-2'), 5.36, 5.52 (2H, 2d, 2'- and 3'-OH), 5.77 (1H, d, H-1'),  
10 5.96 (1H, br s, -NH<sub>2</sub>), 7.27 (1H, t, Ar-H), 7.37 (2H, t, Ar-H), 7.42 (2H,  
d, Ar-H), 7.91, 8.18 (2H, 2s, H-8, N-H).

#### EXAMPLE 16

##### 5'-Chloro-5'-deoxy-2-methylthio-*N*-(1-piperidinyl)adenosine

15 This compound was prepared by general method C, described in more detail in Example 2. 2-Methylthio-*N*-(1-piperidinyl)adenosine [WO 93/23417 (Novo Nordisk A/S)] (0.15 g, 0.38 mmol) was subjected to the chlorination conditions described above, providing  
20 5'-chloro-5'-deoxy-2-methylthio-*N*-(1-piperidinyl)adenosine as a solid (0.07 g, 45%) mp 213 - 215°C.  $^1\text{H-NMR}$  (400MHz, DMSO-d<sub>6</sub>)  $\delta$  1.37  
(2H, br, piperidine C-H), 1.62 (4H, br q, piperidine C-H), 2.48 (3H, s, -SCH<sub>3</sub>), 2.81 (4H, br, piperidine C-H), 3.83, 3.93 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.08 (1H, q, H-4'), 4.23 (1H, q, H-3'), 4.75 (1H, q, H-2'), 5.47,  
25 5.59 (1H, 2d, 2'-and 3'-OH), 5.88 (1H, d, H-1'), 8.22 (1H, s, H-8), 8.85 (1H, s, NH). HPLC retention time 9.15 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 96.4% purity at 250 nm).

- 30 -

EXAMPLE 17

5'-Bromo-2-chloro-5'-deoxy-N-(1-piperidinyl)adenosine

- 5 This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-N-(1-piperidinyl)adenosine [WO 93/08206 (Novo Nordisk A/S)] (3.08 g, 8 mmol) was subjected to the same reaction conditions described above, except that thionyl bromide was substituted for thionyl chloride. The procedure provided the desired
- 10 5'-bromo-2-chloro-5'-deoxy-N-(1-piperidinyl)adenosine as a foam (0.19 g, 9%) after column chromatography, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.37 (2H, br, piperidine C-H), 1.62 (4H, m, piperidine C-H), 2.80 (4H, br, piperidine C-H), 3.72, 3.82 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.10 (1H, dt, H-4'), 4.17 (1H, dt, H-3'), 4.68 (1H, q, H-2'), 5.50, 5.62 (1H, 2d, 2' and 3'-OH), 5.88 (1H, d, H-1'), 8.38 (1H, s, H-8), 9.36 (1H, br, NH). HPLC retention time 11.06 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 96.4% purity at 250 nm).
- 15

C<sub>15</sub>H<sub>20</sub>N<sub>6</sub>BrClO<sub>3</sub>.1.3 H<sub>2</sub>O requires C, 38.2; H, 4.8; N, 17.8. Found: C, 38.7; H, 4.7; N, 17.3%.

EXAMPLE 18

2-Chloro-5'-deoxy-5'-fluoro-N-(1-piperidinyl)adenosine

- 25 This compound was prepared using general method A starting from 1,2,3-tri-O-acetyl-5-deoxy-5-fluoro-D-ribofuranose prepared according to general method B.
- 30 Methyl 5-Deoxy-5-fluoro 2,3-O-(1-methylethylidene)-β-D-ribofuranoside

- 31 -

Methyl 2,3-O-(1-methylethylidene)-5-O-(p-toluenesulfonyl)- $\beta$ -ribofuranoside (28.7 g, 80 mmol) was dissolved in dry acetonitrile (100 ml). Tetra-n-butylammonium fluoride (100 ml, 1.0M in THF) was added dropwise and the reaction mixture was heated at 80°C for 72 h.

- 5 After cooling to room temperature, the mixture was diluted with dichloromethane (200 ml), washed with water (3 x 50 ml) and dried ( $MgSO_4$ ). Evaporation provided a residue which was purified by flash chromatography eluting with a mixture of ethyl acetate and n-heptane (1:3) to give methyl 5-deoxy-5-fluoro-2,3-O-(1-methylethylidene)-  
10 - $\beta$ -D-ribofuranoside (13.6 g, 82%) as a clear oil,  $^1H$  NMR ( $CDCl_3$ ) $\delta$  1.34 (3H, s,  $CH_3$ ), 1.50 (3H, s,  $CH_3$ ), 3.35 (3H, s,  $-OCH_3$ ), 4.29 - 4.48 (3H, m, H-4, H-5<sub>a</sub> and H-5<sub>b</sub>), 4.60 (1H, d, H-3), 4.70 (1H, d, H-2), 4.99 (1H, d, H-1).

15 1,2,3-Tri-*O*-acetyl-5-deoxy-5-fluoro- $\beta$ -D-ribofuranose

- Methyl 5-deoxy-5-fluoro-2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranoside (5.0 g, 24 mmol) was treated with sulfuric acid (0.02M, 40 ml) and heated at reflux for 4 h. The reaction mixture was cooled, neutralized  
20 with barium carbonate to pH 7, filtered and evaporated to an oil. The oil was dried by coevaporation with ethanol, and the residue was dissolved in dichloromethane (50 ml). Acetic anhydride (25 ml) and pyridine (25 ml) were introduced, and the reaction mixture was stirred for 16 h before being poured onto ice (100 ml). The cool suspension was  
25 extracted with dichloromethane (3 x 100 ml), and the combined extracts was washed with 2N hydrochloric acid solution (50 ml) and aqueous sodium bicarbonate solution (50 ml). The organic phase was dried ( $MgSO_4$ ), evaporated in vacuo and the residue was purified by flash chromatography, eluting with a mixture of dichloromethane and 10%  
30 ammonia in ethanol (97:3) to provide 1,2,3-tri-*O*-acetyl-5-deoxy-5--fluoro- $\beta$ -D-ribofuranose (5.3 g, 79%), which crystallized on standing.

- 32 -

Recrystallisation from absolute ethanol provided analytically pure material, m.p. 98 - 101°C, <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.09 (3H, s, -OCOCH<sub>3</sub>), 2.10 (3H, s, -OCOCH<sub>3</sub>), 2.14 (3H, s, -OCOCH<sub>3</sub>), 4.34 (1H, ddd, H-4), 4.49 (1H, ddd, H-5<sub>a</sub>), 4.52 (1H, ddd, H-5<sub>b</sub>), 5.36 (1H, d, H-3), 5.46 (1H, dd, H-2), 6.17 (1H, s, H-1).

C<sub>11</sub>H<sub>15</sub>FO<sub>7</sub> requires C, 47.5; H 5.4. Found: C, 47.7; H, 5.6%.

9-[(2',3'-Di-O-acetyl-5'-deoxy-5'-fluoro-D-ribofuranosyl)]-2,6-dichloro-9H-purine

A mixture of the above

1,2,3-tri-O-acetyl-5-deoxy-5-fluoro-D-ribofuranose (5.0 g, 18 mmol) and 2,6-dichloropurine (3.4 g, 18 mmol) was heated to 160°C. A catalytic

amount of sulfuric acid (one drop) was added at which point a homogeneous melt was obtained. The fusion was continued at 160°C under oil pump vacuum for 0.5 h. After cooling, the reaction mixture was dissolved in chloroform (200 ml) and washed with aqueous sodium bicarbonate (3 x 50 ml) and water (50 ml). The organic phase was dried

(MgSO<sub>4</sub>) and evaporated in vacuo before purification by flash chromatography. Elution with a mixture of dichloromethane and 10% ammonia in ethanol (98:2) afforded an anomeric mixture of 9-[(2',3'-di-O-acetyl-5'-deoxy-5'-fluoro-D-ribofuranosyl)]-2,6-dichloro-9H-purine (4.5 g, 90%) as a gum, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)δ (α-anomer) 1.84 (3H, s, -OCOCH<sub>3</sub>), 2.00

(3H, s, -OCOCH<sub>3</sub>), 4.71 (2H, dd, H-5'a, H-5'b), 5.98 (1H, ddd, H-4'), 5.48 (1H, t, H-3), 5.68 (1H, t, H-2'), 6.73 (1H, d, H-1'), 8.92 (1H, s,

H-8); (β-anomer) 2.05 (3H, s, -OCOCH<sub>3</sub>), 2.11 (3H, s, -COCH<sub>3</sub>), 4.50

(1H, ddd, H-4), 4.77 (2H, dd, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 5.61 (1H, t, H-3), 5.89

(1H, t, H-2'), 6.33 (1H, d, H-1), 8.92 (1H, s, H-8).

- 33 -

**2',3'-Di-O-acetyl-2-chloro-5'-deoxy-5'-fluoro-N-(1-piperidinyl)adenosine:**

An  $\alpha/\beta$  mixture of 9-[(2',3'-di-O-acetyl-5'-deoxy-5'-fluoro-D-ribofuranosyl))-2,6-dichloro-9H-purine (1.24 g, 3.0 mmol), *N,N*-  
5 diisopropylethyl amine (0.79 g, 6.1 mmol) and 1-aminopiperidine (0.60  
g, 6.0 mmol) were stirred in dioxan (20 ml) for 4 h. The reaction mixture  
was diluted with dichloromethane (200 ml) and washed with water (2 x  
50 ml). After drying over ( $MgSO_4$ ) the organic phase was evaporated in  
vacuo and the residue was purified by flash chromatography. Elution  
10 with dichloromethane and 10% ammonia in ethanol (98:2) afforded the  
 $\beta$ -anomer of 2',3'-di-O-acetyl-2-chloro-5'-deoxy-5'-fluoro-N-(1-  
piperidinyl)adenosine (0.40 g, 28%) as a foam. HPLC retention time  
14.8 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA  
in water).

15 The above 2',3'-di-O-acetyl-2-chloro-5'-deoxy-5'-fluoro-N-(1-piperidinyl)-  
adenosine (0.38 g, 0.8 mmol) was dissolved in methanolic ammonia (15  
ml) and stirred for 1 h. The reaction mixture was evaporated in vacuo  
and the resultant residue was purified by flash chromatography eluting  
20 with dichloromethane and 10% ammonia in ethanol (95:5) to afford 2-  
chloro-5'-deoxy-5'-fluoro-N-(1-piperidinyl)adenosine (1.8 g, 86%) as a  
white solid, m.p. 199-201°C.  $^1H$ -NMR (400MHz, DMSO- $d_6$ )  $\delta$  1.35 (2H,  
br, piperidine C-H), 1.52 (4H, br, piperidine C-H), 2.80 (4H, br, piperidine  
C-H), 4.10 (1H, ddd, H-4'), 4.20 (1H, br, H-3'), 4.51 (1H, br, H-2'),  
25 4.65 (2H, dd, H-5' <sub>a</sub> and H-5' <sub>b</sub>), 5.88 (1H, d, H-1'), 8.28 (1H, s, H-8).  
HPLC retention time 7.15 min. (gradient elution over 30 min.; 20-80%  
acetonitrile/0.1% TFA in water).

$C_{15}H_{20}ClFN_6O_3$ , 0.75H<sub>2</sub>O requires C, 45.2; H, 5.4; N, 21.1. Found: C,  
30 45.2; H, 5.2; N, 20.8%.

- 34 -

EXAMPLE 19

2-Chloro-5'-deoxy-5'-fluoro-N-benzyloxyadenosine

5 This compound was prepared by general method A, described in more detail in Example 18 by reacting *O*-benzylhydroxylamine hydrochloride (0.80 g, 5.0 mmol) with 9-[(2',3'-di-*O*-acetyl-5'-deoxy-5'-fluoro-D-ribofuranosyl)]-2,6-dichloro-9H-purine (1.0 g, 2.5 mmol) as described above. The product was purified by flash chromatography  
10 eluting with a mixture of dichloromethane and 10% ammonia in ethanol (98:2) giving the intermediate 2',3'-di-*O*-acetyl-2-chloro-5'-deoxy-5'-fluoro-N-benzyloxyadenosine (0.2 g, 16%). Deacetylation was performed in methanolic ammonia to afford 2-chloro-5'-deoxy-5'-fluoro-N-benzyloxyadenosine as a foam (0.11 g, 89%) after  
15 flash chromatography eluting with dichloromethane and 10% ammonia in ethanol (95:5). <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 4.12 (1H, m, H-4'), 4.20 (1H, m, H-3'), 4.53 (1H, m, H-2'), 4.65 (2H, dd, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 5.00 (2H, s, -CH<sub>2</sub>-), 5.48, 5.60 (2H, 2d, 2'-and 3'-OH) 5.91 (1H, d, H-1'), 7.30 -7.55 (5H, m, Ar-H), 8.43 (1H, s, H-8), 11.65 (1H, s, N-H). HPLC  
20 retention time 14.60 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 96% purity at 250 nm).

EXAMPLE 20

25 (S)-2-Chloro-5'-*O*-methyl-*N*-(2-(methylmethoxy)-1-pyrrolidinyl)adenosine

The title compound was prepared using general method A starting from 5-*O*-methyl-1,2,3-tri-*O*-acetyl-D-ribofuranose, itself prepared according to general method B.

30 Methyl 5-*O*-methyl-2,3-*O*-(1-methylethylidene)-β-D-ribofuranoside.

- 35 -

Methyl 2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranoside (13.3 g, 60 mmol), 2,6-di-t-butyl-4-methylpyridine (20.0 g, 100 mmol) and methyl trifluoromethylsulfonate (16.0 g, 100 mmol) were dissolved in dry dichloromethane (150 ml) placed in a closed reactor and heated to 80°C.

- 5 After cooling, the reaction mixture was poured onto ice (150 ml). After standing, the product was extracted into dichloromethane (2 x 100 ml) and the combined extracts were dried ( $MgSO_4$ ) and evaporated in vacuo. The residue was purified by flash chromatography eluting with a mixture of cyclohexane and ethyl acetate (3:1) to afford methyl 5-O-methyl-2,3-
- 10 O-(1-methylethylidene)- $\beta$ -D-ribofuranoside (8.0 g, 61%) as an oil.  
 $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  1.30 (3H, s, -CH<sub>3</sub>), 1.50 (3H, s, -CH<sub>3</sub>), 3.32 (3H, s, -OCH<sub>3</sub>), 3.39 (3H, s, -OCH<sub>3</sub>), 3.35 - 3.45 (2H, m, H-5<sub>a</sub> and H-5<sub>b</sub>), 4.30 (1H, t, H-4), 4.57 (1H, d, H-3), 4.65 (1H, d, H-2), 4.97 (1H, s, H-1).

- 15 1,2,3-Tri-O-acetyl-5-O-methyl- $\beta$ -D-ribofuranose.

- 5-O-Methyl-2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranoside (3.0 g, 14 mmol) was dissolved in a mixture of sulfuric acid (0.02M, 100 ml) and ethanol (50 ml) and heated at 80°C for 6 h and stirred for 20 h at 20°C. The reaction mixture was neutralised with aqueous sodium bicarbonate and concentrated in vacuo. The residual oil was dried and acetylated in a mixture of dichloromethane (100 ml), acetic anhydride (8.5 g, 83 mmol) and triethylamine (16.7 g, 165 mmol) at 20°C for 20 h. The reaction mixture was washed with hydrochloric acid (1M, 50 ml) and water (50 ml). The organic phase was dried ( $MgSO_4$ ) and concentrated to an oil before being purified by flash chromatography. Elution with a mixture of cyclohexane and ethyl acetate (6:4) provided 1,2,3-tri-O-
- 25 acetyl-5-O-methyl- $\beta$ -D-ribofuranose (2.5g, 62%) as an oil.

- 30 9-(2',3'-Di-O-acetyl-5'-O-methyl- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-

- 36 -

purine

5-O-Methyl-1,2,3-tri-O-acetyl-D-ribofuranose (5.0 g, 17 mmol) and 2,6-dichloropurine (3.3 g, 17 mmol) were thoroughly mixed.

5 A catalytic amount of p-toluene sulfuric acid (50 mg) was added and the reaction mixture was heated to 140°C at which point a homogeneous melt was obtained. The fusion was continued at 140°C under oil pump vacuum for 0.5 h. The reaction mixture was dissolved in chloroform (200 ml) and washed with aqueous sodium bicarbonate (3 x 50 ml) and water (2 x 50 ml). The organic phase was dried ( $MgSO_4$ ), evaporated in vacuo and purified by flash chromatography eluting with a mixture of n-heptane and ethyl acetate (1:1) to provide 9-(2',3'-di-O-acetyl-5'-O-methyl- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-purine (1.0 g, 14%) as an oil which crystallized from diethyl ether. A mixture of  $\alpha$ / $\beta$ -anomers (1.2 g, 17%) was also isolated, with mp 59 - 61°C.  $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  2.06 (3H, s, -OCOCH<sub>3</sub>), 3.49 (3H, s, OCH<sub>3</sub>), 3.67, 3.72 (2H, ABX, H-5', and H-5'<sub>b</sub>), 4.39 (1H, d, H-4'), 5.58 (1H, d, H-3'), 5.75 (1H, t, H-2'), 6.38 (1H, d, H-1'), 8.56 (1H, s, H-8).

20  $C_{15}H_{16}Cl_2N_4O_6$  requires C, 43.0; H, 3.9; N, 13.4. Found C, 43.1, H, 3.9, N, 13.2%.

(S)-2',3'-Di-O-acetyl-2-chloro-5'-O-methyl-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine.

25 9-(2',3'-Di-O-acetyl-5'-O-methyl- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-purine (1.3 g, 3.1 mmol), (S)-N-amino-2-(methoxymethyl)pyrrolidine (0.81 g, 6.2 mmol) and triethylamine (0.63 g, 6.2 mmol) were dissolved in dioxan. After stirring for 20 h the reaction mixture was diluted with 30 dichloromethane (150 ml) and washed with water (2 x 75 ml). The organic phase was dried ( $MgSO_4$ ) and concentrated in vacuo. The

- 37 -

resultant residue was purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (97:3) to afford (S)-2',3'-di-O-acetyl-2-chloro-5'-O-methyl-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine (0.28 g, 18%) as a foam. <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ 1.70 - 2.10 (4H, m, pyrrolidine C-H), 2.05 (3H, s, -OCOCH<sub>3</sub>), 2.18 (3H, s, -OCOCH<sub>3</sub>), 2.85 (1H, m, pyrrolidine C-H), 3.10 (1H, br, pyrrolidine C-H), 3.22 (3H, s, -OCH<sub>3</sub>), 3.35 - 3.70 (8H, m, H-5' and H-5'<sub>b</sub>, -OCH<sub>3</sub>, pyrrolidine, -CH<sub>2</sub>-), 4.32 (1H, s, H-4'), 5.55 (1H, d, H-3'), 5.75 (1H, t, H-3'), 6.32 (1H, d, H-1'), 8.17 (1H, s, H-8). HPLC retention time 15.57 min. (gradient elution over 25 min.; 20-80% acetonitrile/O.1% TFA in water).

The above (S)-2',3'-di-O-acetyl-2-chloro-5'-O-methyl-N-[2-(methylmethoxy)-1-pyrrolidinyl]adenosine (0.26 g, 0.52 mmol) was treated with methanolic ammonia for 1.5 h at room temperature. The crude product was purified by flash chromatography eluting with dichloromethane and 10% ammonia in ethanol (9:1) to give (S)-2-chloro-5'-O-methyl-N-(2-(methylmethoxy)-1-pyrrolidinyl)adenosine (0.16 g, 72%) as a foam. <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.55 (1H, m, pyrrolidine C-H), 1.75 (2H, m, pyrrolidine C-H), 1.97 (1H, m, pyrrolidine C-H), 3.51, 3.59 (1H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.02 (1H, dd, H-4'), 4.10 (1H, dd, H-3'), 4.52 (1H, dd, H-2'), 5.82 (1H, d, H-1'), 8.32 (1H, s, H-8). HPLC retention time 7.67 min. (gradient elution over 25 min.; 20-80% acetonitrile/O.1% TFA in water).

C<sub>17</sub>H<sub>25</sub>CIN<sub>6</sub>O<sub>5</sub>. 0.5H<sub>2</sub>O requires C, 46.3; H, 5.8; N, 18.5. Found C, 46.7; H, 6.1; N, 18.6%.

#### EXAMPLE 21

30

2-Chloro-5'-deoxy-5'-methylthio-N-(1-piperidinyl)adenosine

- 38 -

The title compound was prepared according to general method C.

2-Chloro-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl) adenosine tosylate  
salt

5

2-Chloro-N-(1-piperidinyl)adenosine (1.5 g, 3.9 mmol), 2,2-dimethoxy-  
propane (0.9 g, 8.6 mmol) and 4-toluenesulfonic acid monohydrate (1.6  
g, 18.6 mmol) was stirred in acetone (25 ml) for 72 h. Further 2,2-di-  
methoxypropane (0.9 g, 8.6 mmol) was added. After a further 24 h the  
10 tosylate salt of 2-chloro-2',3'-O-(1-methylethylidene)-N-  
(1-piperidinyl)adenosine (1.78 g, 76%) was collected by filtration, m.p.  
169-170°C, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.35 (3H, s, -CH<sub>3</sub>), 1.46  
(2H, br, piperidine C-H), 1.55 (3H, s, -CH<sub>3</sub>), 1.75 (4H, m, piperidine -  
CH), 3.10 (4H, br, piperidine C-H), 3.55 (2H, ABX, H-5<sub>a</sub>' and H-5<sub>b</sub>'),  
15 4.29 (1H, m, H-4'), 4.95 (1H, dd, H-3'), 5.30 (1H, dd, H-2'), 6.15 (1H,  
d, H-1'), 8.72 (1H, s, H-8). HPLC retention time 14.87 min. (gradient  
elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water).

20 C<sub>25</sub>H<sub>33</sub>ClN<sub>6</sub>O<sub>7</sub>S requires C, 50.3; H, 5.6; N, 14.1. Found C, 50.7; H, 5.8;  
N, 13.7%.

2-Chloro-5'-deoxy-5'-methylthio-2',3'-O-(1-methylethylidene)-N-(1-piper-  
idinyl)adenosine

25 2-Chloro-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl) adenosine tosylate  
(0.5 g, 0.84 mmol), tributylphosphine (1.7 g, 8.4 mmol) and dimethyl-  
disulfide (0.4 g, 4.20 mmol) were stirred in dry dimethylformamide (5  
ml) under nitrogen for 7 days. The reaction mixture was poured into ice  
30 (50 ml) and after standing for 1 h was extracted with dichloromethane  
(3 x 25 ml). The organic phase was dried (MgSO<sub>4</sub>) and evaporated in  
vacuo. The crude product was purified by flash chromatography eluting

- 39 -

with a mixture of dichloromethane and 10% ammonia in ethanol (95:5) to give 2-chloro-5'-deoxy-5'-methylthio-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)adenosine (0.12 g, 31%) as a foam.  $^1\text{H-NMR}$  (400MHz,  $\text{CDCl}_3$ )  $\delta$  1.40 (3H, s, - $\text{CH}_3$ ), 1.45 (2H, m, piperidine C-H), 1.65 (3H, s, - $\text{CH}_3$ ), 1.70 - 1.85 (4H, m, piperidine C-H), 2.15 (3H, s, - $\text{SCH}_3$ ), 2.85 (4H, m, piperidine C-H), 4.02, 4.38 (2H, ABX, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 5.05 (1H, dd, H-4'), 5.38 (1H, dd, H-3'), 6.05 (1H, d, H-2'), 6.50 (1H, br, H-1'), 7.83 (1H, s, H-8).

10      **2-Chloro-5'-deoxy-5'-methylthio-N-(1-piperidinyl)adenosine**

2-Chloro-5'-deoxy-5'-methylthio-2',3'-O-(1-methylethylidene)-N-(1-piperidinyl)adenosine (0.10 g, 0.22 mmol) was reacted in a mixture of water (2.5 ml) and ethanol (2.5 ml) containing sulfuric acid (0.1 ml) for 10 h at 15 60°C. The reaction mixture was diluted with dichloromethane (100 ml) and washed with aqueous sodium bicarbonate (2 x 25 ml) followed by water (25 ml). The organic phase was dried ( $\text{MgSO}_4$ ) and concentrated in vacuo. The crude product was purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (95:5) 20 to provide 2-chloro-5'-deoxy-5'-methylthio-N-(1-piperidinyl)adenosine (0.75 g, 82%) as a foam,  $^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.39 (2H, br, piperidine C-H), 1.62 (4H, m, piperidine C-H), 2.05 (3H, s, - $\text{SCH}_3$ ), 2.75 - 2.80 (8H, m, H-5'<sub>a</sub>, H-5'<sub>b</sub>, piperidine C-H), 4.01 (1H, m, H-4'), 4.10 (1H, m, H-3'), 4.65 (1H, br, H-2'), 6.82 (1H, d, H-1'), 8.39 (1H, s, H-8). 25 HPLC retention time 9.90 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, purity 96% at 250 nm).

EXAMPLE 22

30

2-Chloro-5'-cyano-5'-deoxy-N-(1-piperidinyl)adenosine

- 40 -

The title compound was prepared using general method A starting from 1,2,3-tri-O-acetyl-5-deoxy-5-cyano-D-ribofuranose prepared according to general method B as follows:

- 5      Methyl 2,3-O-(1-methylethylidene)-5-O-(4-nitrobenzenesulfonyl)- $\beta$ -D-ribofuranoside

Methyl 2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranose (37 g, 180 mmol) and triethylamine (54.6 g, 540 mmol) were dissolved in dry dichloromethane (100 ml). 4-Nitrobenzenesulfonyl chloride (40.0 g, 180 mmol) was added dropwise at 0°C over 0.5 h. After stirring for 20 h, the reaction mixture was diluted with dichloromethane (1000 ml) and washed with aqueous ammonium chloride (2 x 250 ml) and water (250 ml). After drying ( $MgSO_4$ ) the organic phase was evaporated to dryness in vacuo. Recrystallization from ethyl acetate gave methyl 2,3-O-(1-methylethylidene)-5-O-(4-nitrobenzenesulfonyl)- $\beta$ -D-ribofuranoside as a white solid (54.8 g, 85%), m.p. 97-98°C,  $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  1.38 (3H, s, -CH<sub>3</sub>), 1.45 (3H, s, -CH<sub>3</sub>), 3.26 (3H, s, -OCH<sub>3</sub>), 4.13 (2H, ABX, H-5<sub>a</sub> and H-5<sub>b</sub>), 4.32 (1H, t, H-4), 4.53 (1H, d, H-3), 4.61 (1H, d, H-2), 4.95 (1H, s, H-1), 8.12 (2H, d, Ar-H), 8.40 (2H, d, Ar-H).

Methyl 5-cyano-5-deoxy-2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranoside.

Methyl 2,3-O-(1-methylethylidene)-5-O-(4-nitrobenzenesulfonyl)- $\beta$ -D-ribofuranoside (45.3 g, 120 mol) was added over 1.5 h to a suspension of sodium cyanide (6.8 g, 140 mmol) in dry dimethylformamide (1000 ml). The reaction mixture was heated to 50°C for 3 h before being poured onto ice (500 ml). This mixture was extracted with dichloromethane (3 x 500 ml), the combined extracts were dried ( $MgSO_4$ ) and concentrated in vacuo. The residue was distilled under vacuum to give methyl 5-cyano-5-deoxy-2,3-O-(1-methylethylidene)- $\beta$ -D-ribofuranoside as an oil (6.3 g,

- 41 -

25%), bp 110-115°C/0.6 mm Hg.  $^1\text{H-NMR}$  (400MHz,  $\text{CDCl}_3$ )  $\delta$  1.30 (3H, s, - $\text{CH}_3$ ), 1.48 (3H, s, - $\text{CH}_3$ ), 2.62, 2.70 (2H, ABX, H-5<sub>a</sub> and H-5<sub>b</sub>), 3.40 (3H, s, - $\text{OCH}_3$ ), 4.45 (1H, s, H-4), 4.61 (1H, d, H-3), 4.63 (1H, d, H-2), 5.00 (1H, s, H-1).

5

Methyl 2,3-di-*O*-benzoyl-5-cyano-5-deoxy- $\beta$ -D-ribofuranoside

Methyl 5-cyano-5-deoxy-2,3-*O*-(1-methylethylidene)- $\beta$ -D-ribofuranoside (18.7 g, 87 mmol) and Amberlyst ( $\text{H}^+$  form, 84 g) were mixed and  
10 heated at reflux for 24 h. The reaction mixture was filtered and evaporated to a residue which was dissolved in dichloromethane (200 ml), which was washed with water (300 ml). The separated water phase was extracted with ethyl acetate (7 x 200 ml), combined with the earlier organic phase and dried ( $\text{MgSO}_4$ ). Evaporation provided the intermediate  
15 methyl 5-cyano-5-deoxy- $\beta$ -D-ribofuranoside (6.85 g) which was dissolved in dichloromethane (200 ml). Benzoyl chloride (24 g, 170 mmol) and triethylamine (34 g, 340 mmol) were introduced and the reaction mixture was stirred for 20 h. at ambient temperature before being washed with 1 N hydrochloric acid solution (2 x 85 ml) and saturated sodium bicarbonate solution. The organic phase was dried ( $\text{MgSO}_4$ ) and evaporated to a residue which was purified by flash chromatography on silica gel. Elution with a mixture of heptane and ethyl acetate (39:1), increasing polarity to a 9:1 mixture of these solvents provided methyl 2,3-*O*-dibenzoyl-5-cyano-5-deoxy- $\beta$ -D-ribofuranoside (13.01 g, 40%).  
25  $^1\text{H-NMR}$  (400MHz,  $\text{CDCl}_3$ )  $\delta$  3.04, 3.20 (2H, ABX, H-5<sub>a</sub> and H-5<sub>b</sub>), 3.43 (3H, s, - $\text{OCH}_3$ ), 4.67 (1H, d, H-4), 5.25 (1H, s, H-1), 5.50 - 5.57 (2H, m, H-3 and H-4), 7.4 - 7.95 (10H, 6m, Ar-H).

1-*O*-Acetyl-2,3-di-*O*-benzoyl-5-cyano-5-deoxy-D-ribofuranose

30

Acetic acid (74.5 ml, 1.3 mol), acetic anhydride (173.8 ml, 1840 mmol)

- 42 -

and sulphuric acid (1.7 ml, 32 mmol) were mixed together and methyl 2,3-O-dibenzoyl-5-cyano-5-deoxy- $\beta$ -D-ribofuranoside (13.01 g, 35 mmol) was added. The reaction mixture was stirred for 20 h at ambient temperature before sodium acetate (37 g, 450 mmol) was introduced. After 5 min. stirring the reaction mixture was filtered, the filter pad was washed with ethyl acetate (100 ml) and the filtrate was evaporated to a residue which was coevaporated with toluene (250 ml). The residue was dissolved in a mixture of ethyl acetate (250 ml) and water (250 ml). The ethyl acetate phase was washed with water (2 x 100 ml) and saturated 10 brine (50 ml) before being dried ( $MgSO_4$ ) and evaporated. The residue was purified by flash chromatography on silica gel. Elution with a mixture of hexane and ethyl acetate (9:1), increasing polarity to a 4:1 mixture of these solvents provided the title 1-O-acetyl-2,3-di-O-benzoyl-5-cyano-5-deoxy-D-ribofuranose as a solid single isomer (2.85 g, 20%), 15 mp 124-126°C,  $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  2.22 (3H, s, -OCOCH<sub>3</sub>), 2.92, 3.02 (2H, ABX, H-5<sub>a</sub> and H-5<sub>b</sub>), 4.61 (1H, dt, H-4), 5.70 - 5.80 (2H, 2m, H-2 and H-3), 6.38 (1H, s, H-1) and a mixture of isomers as a gum (7.5 g, 52%).

20 9-(2',3'-Di-O-benzoyl-5'-cyano-5'-deoxy-D-ribofuranosyl)-2,6-dichloro-9H-purine

A mixture of 1-O-acetyl-2,3-di-O-benzoyl-5-cyano-5-deoxy-D-ribofuranose (2.8 g, 6.8 mmol) and 2,6-dichloro-9H-purine 25 (1.36 g, 7.2 mmol) were heated at 145°C for 1.25 h in the presence of a catalytic amount of p-toluenesulphonic acid (0.025 g). The reaction mixture was dissolved in ethyl acetate (100 ml) and washed with aqueous sodium bicarbonate (100 ml) followed by saturated brine (100 ml). The organic phase was dried ( $MgSO_4$ ), and the solid residue was 30 recrystallised from 2-propanol to provide 9-(2',3'-di-O-benzoyl-5'-cyano-5'-deoxy- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-purine (3.3 g, 90%), m.p.

- 43 -

143-145°C,  $^1\text{H-NMR}$  (400MHz,  $\text{CDCl}_3$ )  $\delta$  3.15, 3.25 (2H, ABX, H-5', and H-5'), 4.74 (1H, dt, H-4'), 5.95 (1H, t, H-3'), 6.12 (1H, t, H-2'), 6.42 (1H, d, H-1'), 7.36 - 8.05 (10H, 4m, Ar-H), 8.40 (1H, s, H-8).

5      2',3'-Di-O-benzoyl-2-chloro-5'cyano-5'-deoxy-*N*-(1-piperidinyl)adenosine

9-(2',3'-di-O-benzoyl-5'-cyano-5'-deoxy- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-purine (1.75 g, 3.25 mmol), triethylamine (0.9 ml, 6.5 mmol) and 1-aminopiperidine (0.7 ml, 6.5 mmol) were stirred in dioxan (20 ml) for 2 h. The reaction mixture was evaporated and the residue dissolved in dichloromethane (10 ml) and purified by flash chromatography eluting with a mixture of heptane and ethyl acetate (4:1), increasing polarity to a 1:1 mixture of these solvents provided 2',3'-di-O-benzyl-2-chloro-5'-cyano-5'-deoxy-*N*-(1-piperidinyl)adenosine (1.19 g, 61%) as a foam, 15       $^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ )  $\delta$  3.15, 3.31 (2H, ABX, H-5' and H-5'), 4.68 (1H, dd, H-4'), 5.99 (1H, t, H-3'), 6.11 (H, t, H-2'), 6.36 (1H, d, H-1'), 7.36 - 8.00 (10H, m, Ar-H), 8.03 (1H, s, H-8). HPLC retention time 17.26 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water).

20

2-Chloro-5'-cyano-5'-deoxy-*N*-(1-piperidinyl)adenosine

2',3'-O-Benzoyl-2-chloro-5'-cyano-5'-deoxy-*N*-(1-piperidinyl)adenosine (1.5 g, 2.5 mmol) was dissolved in methanolic ammonia (30 ml) and 25      stirred at ambient temperature for 3 h. Following evaporation, the crude product was purified by flash chromatography eluting with a mixture of heptane and ethyl acetate, followed by ethyl acetate alone to provide 2-chloro-5'-cyano-5'-deoxy-*N*-(1-piperidinyl)adenosine as a solid (0.6 g, 61%). Recrystallization from ethyl acetate provided an analytical sample 30      (0.36 g, 37%), m.p. 192-193°C,  $^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.38 (2H, br, piperidine C-H), 1.63 (4H, q, piperidine C-H), 2.81 (4H, br,

- 44 -

piperidine C-H), 3.05 (2H, d, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.12 (2H, m, H-4'and H-3'), 4.65 (1H, m, H-2'), 5.53, 5.67 (2H, 2d, 2'-and 3'-OH), 5.87 (1H, d, H-1'), 8.37 (1H, s, H-8). HPLC retention time 11.9 min. (gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium sulfate in water), purity 100% at 250 nm).

C<sub>18</sub>H<sub>20</sub>CIN<sub>7</sub>O<sub>3</sub> requires C, 48.8; H, 5.1; N, 24.9. Found C, 48.9; H, 5.3; N, 24.6%.

10

### EXAMPLE 23

#### 2-Chloro-5'-cyano-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine

This compound was prepared by general method A, described in more detail in Example 22. 2',3'-Di-O-benzoyl-2-chloro-5'-cyano-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine [prepared from 1-amino-6-phenylthiopiperidine (Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666) and 9-(2',3'-di-O-benzoyl-5'-cyano-5'-deoxy-β-D-ribofuranosyl)-2,6-dichloro-9H-purine as described in Example 24] (1.5 g, 2.5 mmol) in methanol (20 ml) was treated with methanolic ammonia (5 ml). The reaction mixture was stirred at ambient temperature for 0.75 h. Ethyl acetate (5 ml) was added to the residue on evaporation to provide 2-chloro-5'-cyano-5'-deoxy-N-(4-phenylthio-1-piperidinyl)adenosine (0.11 g, 46%) as a solid, m.p. 159-161°C, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.68 (2H, br q, piperidine C-H), 1.98 (2H, m, piperidine C-H), 2.78 (2H, br, piperidine C-H), 3.04 (2H, br d, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 4.11 (2H, m, H-4'and H-3'), 4.63 (1H, m, H-2'), 5.54, 5.68 (2H, 2d, 2'-and 3'-OH), 5.88 (1H, d, H-1'), 7.22 - 7.45 (5H, 3m, Ar-H), 8.38 (1H, s, H-8), 9.49 (1H, s, N-H). HPLC retention time 20.34 min. (gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium sulfate in water), purity 96%

- 45 -

at 250 nm).

$C_{16}H_{20}ClN_7O_3$ . 0.7 H<sub>2</sub>O. 0.1 EtOAc requires C, 51.4; H, 5.1; N, 18.7.

Found C, 51.4; H, 4.9; N, 18.3%.

5

EXAMPLE 24

2-Chloro-5'-deoxy-N-(1-piperidinyl)adenosine

- 10 The title compound was prepared using general method A starting from 1-*O*-acetyl-2,3-di-*O*-benzoyl-5-deoxy-D-ribofuranose prepared according to general method B as follows:

Methyl 2,3-di-*O*-benzoyl-5'-deoxy-D-ribofuranoside

- 15 Methyl 5'-deoxy-2,3-*O*-(1-methylethylidene)-D-ribofuranoside (prepared by reduction of methyl 2,3-*O*-(1-methylethylidene)-5'-*O*-(*p*-toluenesulphonyl)-D-ribofuranoside using lithium aluminium hydride) (4.36 g, 23.2 mmol) was dissolved in methanol (120 ml) and Amberlyst resin ( $H^+$  form, 19 g) was introduced. The mixture was stirred at 80°C for 60 h and filtered. The filter pad was washed with methanol and the filtrate was evaporated to an oily residue. The residue was dissolved in dichloromethane and to this solution was added triethylamine (25.7 g, 185 mmol). Benzoyl chloride (13.08 g, 10.8 ml, 92.8 mmol) was added dropwise over 0.5 h and the reaction mixture was stirred at ambient temperature for 40 h. The reaction mixture was extracted with 0.5 M hydrochloric acid solution (2 x 50 ml) and sodium bicarbonate solution (30 ml) before being dried ( $MgSO_4$ ) and evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of heptane and ethyl acetate (4:1), gradually increasing polarity a (1:1) mixture of these solvents, providing the title methyl 2,3-di-*O*-benzoyl-5'-

- 46 -

deoxy-D-ribofuranoside (6.11 g, 74%), <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ 1.50 (3H, d, -CHCH<sub>3</sub>), 3.48 (3H, s, -COCH<sub>3</sub>), 4.48 (1H, q), 5.11 (1H, s), 5.46 (1H, t), 5.60 (1H, d), 7.25 - 8.19 (20H, m, Ar-H).

- 5      9-(2',3'-Di-O-benzoyl-5'-deoxy-β-D-ribofuranosyl)-2,6-dichloro-9H-purine  
10     1-O-Acetyl-2,3-di-O-benzoyl-5'-deoxy-D-ribofuranose [prepared from the  
above methyl 2,3-di-O-benzoyl-5'-deoxy-D-ribofuranoside by the method  
described in Lerner, L. Nucleic Acid Chemistry: Improved and New  
10     Synthetic Procedures, Methods and Techniques, Part Four. Townsend,  
L.B. and Tipson, R.S., Eds.; John Wiley and Sons, New York, 1991, pp  
274 - 280] (1.02 g, 2.65 mmol) and 2,6-dichloro-9H-purine (0.48 g,  
2.53 mmol) were mixed thoroughly and heated at 145°C under oilpump  
vacuum for 2 h. The cooled reaction mixture was dissolved in  
15     dichloromethane (25 ml), evaporated, and coevaporated with toluene (2  
x 50 ml). Purification of the residue by flash chromatography provided  
the title 9-(2',3'-di-O-benzoyl-5'-deoxy-β-D-ribofuranosyl)-2,6-dichloro-  
9H-purine (0.90 g, 58%) as a foam, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ  
1.67 (3H, d, -CHCH<sub>3</sub>), 4.64 (1H, dt, H-4'), 5.72 (1H, t, H-3'), 6.12 (1H,  
20     t, H-2'), 6.35 (1H, d, H-1'), 7.31 - 8.05 (10H, m, Ar-H), 8.31 (1H, s,  
H-8).  
  
2',3'-Di-O-benzoyl-2-chloro-5'-deoxy-N-(1-piperidinyl)adenosine  
25     9-(2',3'-Di-O-benzoyl-5'-deoxy-β-D-ribofuranosyl)-2,6-dichloro-9H-purine  
(0.46 g, 0.75 mmol) was dissolved in dioxan (10 ml). 1-Aminopiperidine  
(0.06 ml, 0.90 mmol) and triethylamine (0.16 ml, 1.13 mmol) were  
added and the reaction mixture was stirred at ambient temperature for  
18 h before being evaporated.  
30     The residue was treated with water (50 ml) and ethyl acetate (100 ml).  
The organic phase was separated and washed with water (2 x 50 ml).

- 47 -

The combined extracts were dried ( $MgSO_4$ ) and evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of heptane and ethyl acetate (1:1) to provide the title 2,3-di-O-benzoyl-2-chloro-5'-deoxy-*N*-(1-piperidinyl)adenosine (0.30 g, 69%) as a foam,

5       $^1H$ -NMR (400MHz,  $CDCl_3$ ) 1.48 (2H, br, piperidine C-H), 1.80 (2H, m, piperidine C-H), 2.87 (2H, br, piperidine C-H), 4.57 (1H, dt, H-4'), 5.71 (1H, t, H-3'), 6.07 (1H, t, H-2'), 6.33 (1H, d , H-1'), 7.28 - 8.00 (11H, m, Ar-H and H-8).

10      **2-Chloro-5'-deoxy-*N*-(1-piperidinyl)adenosine**

2,3-Di-O-benzoyl-2-chloro-5'-deoxy-*N*-(1-piperidinyl)adenosine (0.30 g, 0.81 mmol) was dissolved in methanol (10 ml) and methanolic ammonia (5 ml) was introduced. The reaction mixture was stirred at ambient

15      temperature for 18 h. and evaporated. The residue was purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (95:5) to provide the title  
2-chloro-5'-deoxy-*N*-(1-piperidinyl)adenosine (0.13 g, 43%) as a foam,  
20       $^1H$ -NMR (400MHz,  $DMSO-d_6$ )  $\delta$  1.21 - 1.43 (5H, m, piperidine C-H and  $CHCH_3$ ), 1.63 (4H, br q, piperidine C-H), 2.82 (4H, br m, piperidine C-H), 5.79 (1H, d, H-1'), 8.37 (1H, s, H-8), 9.32 (1H, s, N-H). HPLC retention time 6.82 min. (gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium sulfate in water).

25

EXAMPLE 25

2-Chloro-5'-deoxy-5'-methylene-*N*-(1-piperidinyl)adenosine

Methyl 5-deoxy-5'-methylene-2,3-*O*-(1-methylethylidene)-D-ribo-

30      furanoside

- 48 -

Triphenylmethylphosphonium bromide (26.79 g, 75 mmol) was suspended in THF (200 ml) and n-butyllithium (1.7M in hexanes) (42 ml, 71.2 mmol) was introduced. After stirring for 2 h, methyl 5-deoxy-5-oxo-2,3-O-(1-methylethylidene)-D-ribofuranoside (prepared by oxidation of 1-  
5 O-methyl-2,3-O-(1-methylethylidene)-D-ribofuranoside using the method described in Ranganathan, R.S., Jones, G.H. and Moffatt, J.G., Journal of Organic Chemistry, 1974, 39(3), 290-298) (5.06 g, 25 mmol) in THF (50 ml) was added dropwise. The reaction mixture was heated for 2 h at 50°C and cooled. A mixture of water (10 mL) and THF (90 ml) were  
10 added carefully under a stream of nitrogen. Diethyl ether (250 ml) and water (250ml) were introduced. The aqueous phase was washed with diethyl ether (250 ml) and the combined organic extracts were washed with saturated brine (150 ml) and dried ( $MgSO_4$ ). The residue on evaporation was purified by flash chromatography eluting with a mixture of  
15 cyclohexane and ethyl acetate (19:1), increasing polarity to a mixture of heptane and ethyl acetate (9:1) provided the desired methyl 5-deoxy-2,3-O-(1-methylethylidene)-5-methylene-D-ribofuranoside (3.6 g, 72%) as a gum,  $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  1.32, 1.50 (6H, 2s,  $C(CH_3)_2$ ), 3.36 (3H, s, -COCH<sub>3</sub>), 4.64 (1H, s), 4.65 (1H, d), 5.00 (1H, s), 5.15  
20 (1H, d), 5.26 (1H, d), 5.83 - 5.92 (1H, m).

Methyl 2,3-di-O-benzoyl-5-deoxy-5-methylene-D-ribofuranoside

Methyl 5-deoxy-2,3-O-(1-methylethylidene)-5-methylene-D-ribofuranoside  
25 (5.65 g, 28.2 mmol) was dissolved in methanol (250 ml) and Amberlyst resin ( $H^+$  form, 30 g) was introduced. The mixture was stirred at ambient temperature for 40 h and was filtered. The filter pad was washed with methanol and the filtrate was evaporated to an oily residue. The residue was dissolved in dichloromethane and to this solution was added  
30 benzoyl chloride (8.47 g, 7.0 ml, 60 mmol) and triethylamine (6.49 g, 8.94 ml, 66 mmol) and the reaction mixture was stirred at ambient

- 49 -

temperature for 18 h. The reaction mixture was extracted with 0.5 M hydrochloric acid solution (2 x 100 ml) and water (100 ml) before being dried ( $MgSO_4$ ) and evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of heptane and ethyl

5 acetate (29:1), gradually increasing polarity to a (4:1) mixture of these solvents, providing the title methyl 2,3-di-O-benzoyl-5-deoxy-5-methylene-D-ribofuranoside (1.66 g, 26%),  $^1H$ -NMR (400MHz,  $CDCl_3$ )  $\delta$  3.50 (3H, s, -COCH<sub>3</sub>), 4.75 - 4.82 (1H, m), 5.16 (1H, s), 5.30 (1H, d), 5.45 (1H, d), 5.61 (1H, d), 5.94 - 6.09 (1H, m).

10

9-(2',3'-Di-O-benzoyl-5'-deoxy-5'-methylene- $\beta$ -D-ribofuranosyl)-2,6-dichloro-9H-purine

15 1-O-Acetyl-2,3-di-O-benzoyl-5-deoxy-5-methylene-D-ribofuranose [prepared from the above methyl 2,3-di-O-benzoyl-5-deoxy-(1-methylethyldene)-5-methylene-D-ribofuranoside by the method described in Lerner, L. Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques, Part Four. Townsend, L.B. and Tipson, R.S., Eds.; John Wiley and Sons, New York, 1991, pp 274 - 280] (4.2 g, 10.6 mmol) and 2,6-dichloro-9H-purine (2.0 g, 10.6 mmol) were suspended in dichloromethane (25 ml) and evaporated to a residue which was heated at 150°C under oilpump vacuum for 1.5 h. The cooled reaction mixture was dissolved in dichloromethane (25 ml), evaporated, and coevaporated with toluene (2 x 50 ml). Purification of 25 the residue by flash chromatography eluting with a mixture of heptane and ethyl acetate (9:1), increasing polarity to a mixture of heptane and ethyl acetate (4:1) provided the title 2,6-dichloro-9-(5'-deoxy-2',3'-di-O-benzoyl-5'-methylene- $\beta$ -D-ribofuranosyl)-9H-purine (3.98 g, 71%) as a foam,  $^1H$ -NMR (400MHz,  $DMSO-d_6$ )  $\delta$  4.98 (1H, d), 5.48 (1H, d), 5.58 (1H, d), 5.91 (1H, t), 6.16 (1H, t, H-2'), 6.22 (1H, m), 6.44 (1H, d, H-1'), 7.34 - 8.08 (10H, m, Ar-H), 8.34 (1H, s, H-8). HPLC retention

30

- 50 -

time 15.51 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water).

5        2',3'-Di-O-benzoyl-2-chloro-5'-deoxy-5'-methylene-N-(1-piperidinyl)-adenosine

2,6-Dichloro-9-(5'-deoxy-2',3'-di-O-benzoyl-5'-methylene- $\beta$ -D-ribofuranosyl)-9H-purine (0.3 g, 0.57 mmol) was dissolved in dioxan (20 ml). 1-Aminopiperidine (0.066 g, 0.63 mmol) and triethylamine (0.087 g, 10 0.12 ml, 0.86 mmol) were added and the reaction mixture was stirred at ambient temperature for 40 h and evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of heptane and ethyl acetate (4:1), gradually increasing polarity to a (1:1) mixture of these solvents, to afford the title 2,3-di-O-benzoyl-2-chloro-5'-deoxy-15 5'-methylene-N-(1-piperidinyl)adenosine (0.28 g, 83%),  $^1\text{H-NMR}$  (400MHz,  $\text{CDCl}_3$ )  $\delta$  4.93 (1H, dt), 5.43 (1H, dd), 5.56 (1H, d), 5.89 (1H, t), 6.10 (1H, t, H-2'), 6.21 (1H, m), 6.42 (1H, d, H-1'), 7.33 - 8.05 (10H, m, Ar-H).

20      2-Chloro-5'-deoxy-5'-methylene-N-(1-piperidinyl)adenosine

2,3-Di-O-benzoyl-2-chloro-5'-deoxy-5'-methylene-N-(1-piperidinyl)-adenosine (0.28 g, 0.47 mmol) was dissolved in methanolic ammonia (10 ml) and stirred at ambient temperature for 18 h. The reaction mixture was evaporated and purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (95:5) to provide the title 2-chloro-5'-deoxy-5'-methylene-N-(1-piperidinyl)-adenosine (0.081 g, 45%) as a foam,  $^1\text{H-NMR}$  (400MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.30 - 1.45 (2H, br m, piperidine C-H); 1.62 (4H, br q, piperidine C-H), 2.84 (4H, br, piperidine C-H), 4.07 (1H, dt, H-3'), 4.32 (1H, q, H-2'), 30 4.58 (1H, m, H-4'), 5.20 (1H, dd, C=C-H), 5.30 (1H, d, C=C-H), 5.40,

- 51 -

5.56 (2H, 2d, 2'-and 3'-OH), 5.86 (1H, d, H-1'), 6.07 (1H, m, C=C-H),  
8.36 (1H, s, H-8), 9.34 (1H, s, N-H). HPLC retention time 9.35 min.  
(gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium  
sulfate in water), purity 99.5% at 250 nm.

5

EXAMPLE 26

2-Chloro-5'-deoxy-5'-methylene-N-(4-phenylthio-1-piperidinyl)adenosine

10

2',3'-Di-O-benzoyl-2-chloro-5'-deoxy-5'-methylene-N-(4-phenylthio-1-piperidinyl)adenosine, prepared as described in Example 25 from 2,6-dichloro-9-(5'-deoxy-2',3'-di-O-benzoyl-5'-methylene-β-D-ribofuranosyl)-9H-purine (1.0 g, 1.9 mmol) and 1-amino-4-phenylthiopiperidine (0.44 g, 2.1 mmol), was dissolved in methanol (20 ml) and sat. methanolic ammonia (2.5 ml) was introduced. The reaction mixture was stirred at ambient temperature for 18 h, evaporated and purified by flash chromatography eluting with a mixture of dichloromethane and ethanol (50:1) to provide the title 2-chloro-5'-deoxy-5'-methylene-N-(4-phenylthio-1-piperidinyl)adenosine (0.27 g, 29%) as a foam, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.70 (2H, br q, piperidine C-H), 1.99 (2H, br d, piperidine C-H), 2.77 (2H, br m, piperidine C-H), 3.06 (2H, br m, piperidine C-H), 4.07 (1H, q, H-3'), 4.32 (1H, dt, H-2'), 4.58 (1H, m, H-4'), 5.20 (1H, dd, C=C-H), 5.29 (1H, d, C=C-H), 5.39, 5.56 (2H, 2d, 2'-and 3'-OH), 5.86 (1H, d, H-1'), 6.07 (1H, m, C=C-H), 7.23 - 7.45 (5H, 3 m, Ar-H), 8.36 (1H, s, H-8), 9.34 (1H, s, N-H). HPLC retention time 13.46 min. (gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium sulfate in water), purity 100% at 250 nm).

20

25

- 52 -

EXAMPLE 27

2-Chloro-5'-deoxy-N-methoxy-5'-methyleneadenosine

5      2',3'-Di-*O*-benzoyl-2-chloro-5'-deoxy-*N*-methoxy-5'-methyleneadenosine (0.2 g, 0.4 mmol), prepared by the method described in Example 25 from 2,6-dichloro-9-(2',3'-di-*O*-benzoyl-5'-methylene- $\beta$ -D-ribofuranosyl)-9H-purine (0.5 g, 2.0 mmol) and *O*-methylhydroxylamine hydrochloride (0.167 g, 2.0 mmol), was treated with methanolic ammonia (10 ml) and  
10     stirred at ambient temperature for 18 h. The reaction mixture was evaporated and purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (19:1) to provide the title 2-chloro-5'-deoxy-*N*-methoxy-5'-methyleneadenosine (0.03 g, 9%) as a foam,  $^1\text{H}$ -NMR (400MHz, DMSO- $d_6$ )  $\delta$  3.79 (3H, s, -CH<sub>3</sub>), 4.08 (1H, q, H-3'), 4.33 (1H, dt, H-2'), 4.61 (1H, m, H-4'), 5.20 (1H, dd, C=C-H), 5.31 (1H, d, C=C-H), 5.42, 5.59 (2H, 2d, 2'-and 3'-OH), 5.89 (1H, d, H-1'), 6.08 (1H, m, C=C-H), 8.44 (1H, s, H-8), 11.58 (1H, s, N-H). HPLC retention time 7.09 min. (gradient elution over 30 min; 25-45% acetonitrile/0.1% ammonium sulfate in water), purity 98.6% at 250 nm).

15

20

EXAMPLE 28

2-Chloro-5'-deoxy-5'-methylene-*N*-cyclopentyladenosine

25      2,3-Di-*O*-benzoyl-2-chloro-5'-deoxy-5'-methylene-*N*-cyclopentyladenosine (prepared by reaction of 2,6-dichloro-9-(5'-deoxy-2',3'-di-*O*-benzoyl-5'-methylene- $\beta$ -D-ribofuranosyl)-9H-purine with cyclopentylamine) (0.30 g, 0.52 mmol) was dissolved in methanolic ammonia (10 ml) and stirred at ambient temperature for 18 h. The reaction mixture was evaporated and  
30     purified by flash chromatography eluting with a mixture of dichloromethane and 10% ammonia in ethanol (39:1) to provide the title

- 53 -

2-chloro-5'-deoxy-5'-methylene-*N*-cyclopentyladenosine (0.051 g, 27%) as a foam, <sup>1</sup>H-NMR (400MHz, DMSO-d<sub>6</sub>) δ 1.48 - 2.04 (8H, 3 br m, cyclopentyl C-H), 4.08 (1H, q, H-3'), 4.32 (1H, dt, H-2'), 4.42 (1H, m, -HN-C-H), 4.59 (1H, m, H-4'), 5.19 (1H, dd, C=C-H), 5.30 (1H, d, C=C-H), 5.40, 5.55 (2H, 2d, 2'-and 3'-OH), 5.85 (1H, d, H-1'), 6.08 (1H, m, C=C-H), 8.34 (1H, s & br s, H-8 and N-H).

EXAMPLE 29

10      5'-Deoxy-2,5'-dichloro-*N*-(4-phenylthiocyclohexyl)adenosine


This compound was prepared by general method C, described in more detail in Example 2. 2-Chloro-*N*-(4-phenylthiocyclohexyl)adenosine (prepared from 4-hydroxycyclohexlamine by the general methods laid out 15 in Knutsen, L.J.S., Lau, J., Sheardown, M.J., Thomsen, C.; Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2661-2666) (0.2 g, 0.44 mmol) was subjected to the reaction conditions described above, and the residue on evaporation was purified by flash chromatography on silica gel eluting with a mixture of heptane and ethyl acetate (4:1), gradually 20 increasing polarity to a (19:1) mixture of ethyl acetate and methanol to afford the title 5'-deoxy-2,5'-dichloro-*N*-(4-phenylthiocyclohexyl)-adenosine (0.08 g, 38%), <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ 1.20 - 1.30 (2H, t, cyclohexyl C-H), 1.80 - 2.05 (6H, br m, cyclohexyl C-H), 3.75 - 3.84 (2H, m, H-5'<sub>a</sub> and H-5'<sub>b</sub>), 5.96 (1H, d, H-1'), 7.19 - 7.33 (3H, m, Ar-H), 25 7.41 (2H, d, Ar-H), 7.99 (1H, s, H-8), 8.29 (1H, s, N-H). HPLC retention time 9.1 min. (gradient elution over 30 min.; 20-80% acetonitrile/0.1% TFA in water, 100% purity at 250 nm).

- 54 -

CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof

5



10


wherein

- 15 X is halogen, amino, perhalomethyl, cyano, C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino;

A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;


20

R<sup>1</sup> is selected from the groups consisting of



- 25 wherein Q is nitrogen or carbon, n is 1 to 3 and where the group (a) may be optionally substituted with one or two C<sub>1-6</sub>-alkyl groups, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, phenoxy, phenylsulphonyl, phenylsulphanyl, phenylthio, hydroxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, phenylthioalkyl or

30



- 55 -

wherein Y is O, S or NZ, where Z is H, C<sub>1-6</sub>-alkyl or phenyl, and where the group (b) may be optionally substituted with C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, phenoxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, or

5 R<sup>1</sup> is -NR<sup>2</sup>R<sup>3</sup> or -YR<sup>4</sup>,

wherein Y is oxygen or sulphur;

R<sup>2</sup> is C<sub>1-6</sub>-alkyl;

R<sup>3</sup> is phenyl or C<sub>1-6</sub>-alkyl which may be substituted by phenyl or phenoxy;

10 R<sup>4</sup> is C<sub>1-6</sub>-alkyl or C<sub>3-8</sub>-cycloalkyl, which may be substituted by phenyl or phenoxy.

2. A compound of claim 1, wherein


X is halogen, amino, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino;

15

A is methyl, halomethyl, cyanomethyl, vinyl, methylthiomethyl or methoxymethyl;

R<sup>1</sup> is

20



wherein Q is nitrogen or carbon, n is 1 to 3 and where the group (a) may be optionally substituted with one or two C<sub>1-6</sub>-alkyl groups, C<sub>2-6</sub>-alkenyl,

25

C<sub>2-6</sub>-alkynyl, phenoxy, phenylsulphonyl, phenylsulphanyl, phenylthio, hydroxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl, phenylthioalkyl.

3. A compound of claim 1, wherein

X is halogen, amino, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino;

30


A is methyl, halomethyl, cyanomethyl, vinyl, methylthiomethyl or meth-

- 56 -

oxymethyl;

R<sup>1</sup> is

5



(b)

wherein Y is O, S or NZ, where Z is H, C<sub>1-6</sub>-alkyl or phenyl, and where the group (b) may be optionally substituted with C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, phenoxy, phenyl, C<sub>1-6</sub>-alkoxy or C<sub>1-6</sub>-alkoxy-C<sub>1-6</sub>-alkyl.

10

4. A compound of claim 1, wherein

X is halogen, amino, C<sub>1-6</sub>-alkylthio or C<sub>1-6</sub>-alkylamino;

15 A is methyl, halomethyl, cyanomethyl, vinyl, methylthiomethyl or methoxymethyl;

R<sup>1</sup> is -NR<sup>2</sup>R<sup>3</sup> or -YR<sup>4</sup>,

wherein Y is oxygen or sulphur;

20 R<sup>2</sup> is C<sub>1-6</sub>-alkyl;

R<sup>3</sup> is phenyl or C<sub>1-6</sub>-alkyl which may be substituted by phenyl or phenoxy;

R<sup>4</sup> is C<sub>1-6</sub>-alkyl or C<sub>3-8</sub>-cycloalkyl, which may be substituted by phenyl or phenoxy.

25

5. A pharmaceutical composition comprising as active component a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

30 6. A pharmaceutical composition according to claim 5 in the form of an oral dosage unit containing about 1-200 mg of the active compound.

- 57 -

7. A method of treating a central nervous system ailment in a person in need of such treatment characterized in administering to said person an amount of a compound of claim 1 effective in alleviation of such an ailment.

5

8. A method of treating a central nervous system ailment in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of claim 1 which is effective for the alleviation of such ailment in the form of a pharmaceutical composition 10 thereof, in which it is present together with a pharmaceutically acceptable carrier or diluent.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00344

## A. CLASSIFICATION OF SUBJECT MATTER

**IPC6: C07H 19/16, C07H 19/167, A61K 31/70**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

**IPC6: C07H, A61K**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**SE,DK,FI,NO classes as above**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO, A1, 9323417 (NOVO NORDISK A/S), 25 November 1993 (25.11.93)  --	1-6
X	WO, A1, 9308206 (NOVO NORDISK A/S), 29 April 1993 (29.04.93)  --	1-6
Y	EP, A2, 0232813 (WARNER-LAMBERT COMPANY), 19 August 1987 (19.08.87)  --	1-6

 Further documents are listed in the continuation of Box C. See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search  <b>20 December 1994</b>	Date of mailing of the international search report  <b>28 -12- 1994</b>
--	---

Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer  <b>Eva Johansson</b> Telephone No. + 46 8 782 25 00
---	--

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00344

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	STN International, File CA, Chemical Abstracts, volume 103, no. 19, 11 November 1985 (Columbus Ohio, US), Kusachi Shozo et al: "Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion", abstract no. 153334g, & J. Med. Chem., 28(11), 1636-43 --	1-6
Y	STN International, File CA, Chemical Abstracts, volume 79, no. 19, 12 November 1973 (Columbus, Ohio, US), Fujii, Tozo et al: "Purines. XII. Catalytic hydrogenolysis of alkoxyaminopurines and related derivatives", abstract no. 115832w, & Chem. Pharm. Bull., 21(8), 1835-8 --	1-6
Y	STN International, File CA, Chemical Abstracts, volume 79, no. 17, 29 October 1973 (Columbus Ohio, US), Fujii, Tozo et al: "Purines. XI. Synthesis of N-alkoxyadenosines and their 2', 3'-O-isopropylidene derivatives", abstract no. 105513d, & Chem. Pharm. Bull., 21(8), 1676-82 --	1-6
Y	STN International, File CA, Chemical Abstracts, volume 69, no. 13, 23 September 1968 (Columbus Ohio, US), Giner-Sorolla, A. et al: "The synthesis and biological properties of hydroxylaminopurines and related derivatives", abstract no. 52103e, & J. Med. Chem., 11(3), 521-3 --	1-6
Y	WO, A1, 8504882 (NELSON RESEARCH AND DEVELOPMENT COMPANY), 7 November 1985 (07.11.85) --	1-6
A	DE, A, 1545645 (BOEHRINGER MANNHEIM GMBH), 21 August 1969 (21.08.69) -----	1-6

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 94/00344

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 7, 8  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

26/11/94

International application No.

PCT/DK 94/00344

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 9323417	25/11/93	NONE		
WO-A1- 9308206	29/04/93	CA-A- 2121844 EP-A- 0609375 FI-A,D- 941876		29/04/93 10/08/94 22/06/94
EP-A2- 0232813	19/08/87	AU-B- 592728 AU-A- 6797287 CA-A- 1270821 JP-A- 62228095 US-A- 4755594		18/01/90 06/08/87 26/06/90 06/10/87 05/07/88
WO-A1- 8504882	07/11/85	AU-B- 582359 AU-A- 4219585 CA-A- 1293721 CA-A- 1293722 CA-A- 1305135 DE-D,T- 3587717 EP-A,B- 0180614 SE-T3- 0180614 EP-A- 0300144 EP-A- 0300145 EP-A,B- 0305643 JP-T- 61501914 US-A- 5043325		23/03/89 15/11/85 31/12/91 31/12/91 14/07/92 28/04/94 14/05/86 25/01/89 25/01/89 08/03/89 04/09/86 27/08/91
DE-A- 1545645	21/08/69	CH-A- 486487 CH-A- 491952 FR-A- 1503243 GB-A- 1101108 NL-A- 6617087 US-A- 3475408		28/02/70 15/06/70 00/00/00 00/00/00 07/06/67 28/10/69